University of South Florida Patent applications |
Patent application number | Title | Published |
20160139561 | FULL-COLOR INCOHERENT DIGITAL HOLOGRAPHY - In one embodiment, a color holographic image is created by generating a separate complex hologram for each of multiple different colors of an object field illuminated with incoherent light, combining the separate complex holograms to obtain a color complex hologram, and generating a reconstructed color holographic image of the object field. | 05-19-2016 |
20160109776 | Metal Sensitized Color Changing Material - The subject invention pertains to color changeable, film materials comprising a metal substrate layer; a conducting polymer or conducting polymer composite layer; and an electrolyte layer. The conducting polymer or conducting polymer composite layer of the film material is capable of exhibiting changes in one or more optical properties when the film material is in contact with a metal. The subject invention also pertains to methods of preparing conducting polymer films capable of exhibiting changes in optical properties. | 04-21-2016 |
20160108108 | INFLAMMATORY DISEASE DIAGNOSIS AND METHODS OF TREATMENT USING LIPOPOLYSACCHARIDES-RESPONSIVE BEIGE-LIKE ANCHOR - Anti-cytokine therapy has revolutionized immunological disease treatment, but is not always effective and subject to treatment resistance as the cytokine cascade is highly redundant and multiple cytokines are involved in inflammation. Targeting a critical common regulator of inflammatory effectors is desirable. Lipopolysaccharide (LPS)-responsive beige-like anchor (LRBA) is a master regulator of multiple genes important for inflammation. Subcellular localization shows that LRBA translocated to the nucleus upon LPS stimulation and colocalized with multiple proteins associated with the endosome membrane system, indicating a critical role in membrane/vesicle trafficking essential for deposition, secretion and signal transduction of immune effectors. Deregulation, deficiency, down-regulation and overexpression of LRBA causes defective trafficking and signaling of immune effector molecules, resulting in immunodeficiency and autoimmunity diseases associated with a broader spectrum of severe symptoms when compared to other CVID genes. Modulating LRBA through antibodies, dominant negative mutants, or small interference RNA can be used to treat inflammatory diseases. | 04-21-2016 |
20160106997 | PREVENTION AND TREATMENT OF BRAIN DISEASES AND DISORDERS RELATED TO ABNORMAL PROTEIN AGGREGATION THROUGH ELECTROMAGNETIC FIELD TREATMENT - A method of treating and preventing a neurological disorder, such as Alzheimer's disease, in a subject in need thereof by positioning an electromagnetic field emitting source proximal to the subject and exposing the subject to an electromagnetic field having a predetermined frequency (preferably ≈300-3,000 MHz) for a predetermined absorption period (preferably greater than ≈3 days). Each individual treatment (comprising exposure to the predetermined frequency for the predetermined absorption period) is continued at a predetermined schedule for a predetermined treatment period. The EMF can have a specific absorption rate up to about 8 W/kg. The methodology enhances cognition in the subject and/or treats/prevents the underlying neurological disorder or a symptom thereof. | 04-21-2016 |
20160106767 | USE OF PKC-IOTA INHIBITORS FOR THE TREATMENT OF BREAST CANCER - The subject invention pertains to uses of PKC-iota inhibitors for treatment of breast cancer. In one embodiment, the subject invention provides novel uses of 1H-imidazole-4-carboxamide, 5-amino-1-[2,3 -dihydroxy-4-[(phosphonooxy) methyl]cyclopentyl]-,[1R-(1α, 2β, 3β, 4α)] (ICA-1) and related compounds for treatment of breast cancer. The compounds of the subject invention have potent anti-proliferative effects against human breast cancer cells. The compounds of the subject invention also inhibit the phosphorylation of IKK-α/IKK-β, induce chromatin condensation, and/or induce DNA fragmentation in cancer cells. | 04-21-2016 |
20160089344 | NANOPARTICLE TARGETED DRUG DELIVERY TO THE LUNGS USING EXTRA-TESTICULAR SERTOLI CELLS - A method of delivering a compound of interest to the lungs of a subject by the intravenous injection of Sertoli cells loaded with a plurality of chitosan nanoparticles coupled with the compound of interest is provided. Testis-derived rat Sertoli cells were pre-loaded with chitosan nanoparticles coupled with or without the drug curcumin, pre-labeled with a fluorescent cell marker and then injected intravenously into the control or asthmatic mouse model host. Intact pre-loaded, pre-labeled Sertoli cells were present in the lungs at 15 minutes post-injection, appeared entrapped in the pulmonary pre-capillary vascular bed around alveolar sacs but were not present one hour post-injection although Sertoli cell label and cellular debris was. Most of the injected nanoparticle load (70%) and curcumin load (80%) was present in the lungs 15 minutes post-injection, and remained at 70% and 80%, respectively, one hour post-injection. | 03-31-2016 |
20160067207 | COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS - Beta-hydroxybutyrate mineral salts in combination with medium chain fatty acids or an ester thereof such as medium chain triglycerides were used to induce ketosis, achieving blood ketone levels of (2-7 mmol/L), with or without dietary restriction. The combination results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance in a short period of time. Further, use of these supplements to achieve ketosis yields a significant elevation of blood ketones and reduction of blood glucose levels. Use of these substances does not adversely affect lipid profiles. By initiating rapid ketosis and accelerating the rate of ketoadaptation, this invention is useful for the avoidance of glucose withdrawal symptoms commonly experienced by individuals initiating a ketogenic diet, and minimizes the loss of lean body mass during dietary restriction. | 03-10-2016 |
20160053319 | MICRO-RNAS MODULATING IMMUNITY AND INFLAMMATION - MicroRNAs are shown to be up- and/or down-regulated in inflammation and immune cells using a mouse model of asthma and regulatory T cells as source of RNA, respectively. Modulating the expression of these microRNAs can be effective in redirecting inflammation and immunity and hence, can be beneficial as biomarkers or as therapeutic agents against diverse human immunologic and inflammatory diseases. | 02-25-2016 |
20160052941 | ORGANIC ANION LITHIUM IONIC COCRYSTAL COMPOUNDS AND COMPOSITIONS - A cocrystal having the formula LiX.aM, or a solvate or hydrate thereof, wherein X is a conjugate base of an organic acid, M is a neutral organic molecule, and a is from 0.5 to 4, pharmaceutical compositions comprising such cocrystals, cocrystal solvates, or cocrystal hydrates, and methods of preparing such cocrystals, cocrystal solvates, or cocrystal hydrates, and such pharmaceutical compositions. | 02-25-2016 |
20160043314 | METHOD OF MANUFACTURING INVERTED ORGANIC SOLAR MICROARRAY FOR APPLICATIONS IN MICROELECTROMECHANICAL SYSTEMS - The fabrication and characterization of large scale inverted organic solar array fabricated using all-spray process is disclosed. Solar illumination has been demonstrated to improve transparent solar photovoltaic devices. The technology using SAM has potential to revolute current silicon-based photovoltaic technology by providing a complete solution processable manufacturing process. The semi-transparent property of the solar module allows for applications on windows and windshields. The inventive arrays are more efficient than silicon solar cells in artificial light environments, permitting use of the arrays in powering microelectromechanical systems and in integration with microelectromechanical systems. | 02-11-2016 |
20160030483 | MATERIALS AND METHODS FOR TREATING ALLERGIC AND INFLAMMATORY CONDITIONS - The subject invention provides for the utilization of bone-marrow derived stem cells in the treatment of allergic and inflammatory diseases. In one embodiment, the invention provides for treatment of asthma. Bone-marrow derived stem cells can be used for decreasing inflammation and alter the course of immune response in the lung. | 02-04-2016 |
20160030388 | DITERPENOID MEMBRANOLIDE COMPOUNDS HAVING ANTI-LEISHMANIA ACTIVITY AND USES THEREOF - In a screening program, the Antarctic sponge | 02-04-2016 |
20160015286 | INTEGRATED VECTORCARDIOGRAM SYSTEM AND METHOD OF USE - An integrated vectorcardiogram (VCG) device having 3 pairs of electrodes placed in three orthogonal directions with the capability to continuously measure the electrical activity of the heart. All of the electrode pairs may be contained within a single miniaturized housing thereby eliminating the need for cumbersome wires required with current 12-lead ECG systems, while providing the same amount and quality of information as the 12-lead ECG system. The integrated VCG device also includes a communications function to allow the data collected by the electrodes to be transmitted wirelessly to a remote device, such as a pacemaker, to control its function or to a remote monitoring station for continuous real-time patient monitoring. | 01-21-2016 |
20160003825 | USE OF PKC-ZETA AS A BREAST CANCER TUMORIGENIC BIOMARKER AS WELL AS A TARGET FOR TREATMENT OF BREAST CANCER - The present invention provides use of protein kinase C-zeta (PKC-ζ) as a diagnostic biomarker for breast cancer tumorigenesis. Also provided are uses of PKC-zeta inhibitors for inhibiting breast cancer tumorigenesis and for treatment of breast cancer. | 01-07-2016 |
20160002702 | BLUE COLLAGENASE ASSAY - A method of measuring soluble or insoluble cell or tissue-associated collagenase activity. The substrate includes native (fibrillar) collagen fragments that were stained with Coomassie Brilliant Blue R-250. Incubation with collagenase can be observed in real-time by the generation of digested smaller fragments. The degraded blue fragments are obtained by filtration through class fibers, onto which intact collagen fibrils are retained. The filtrate containing the blue collagen fragments is incubated with a detergent in order to extract the blue dye, and the mixture is centrifuged in order to separate the dye in the supernatant from the pellet, which contains de-stained collagen fragments and other insoluble materials contained in the test samples (such as bacterial cells or tissues). The amount of dye extracted is quantified by measuring the amount of dye extracted from these fragments, i.e., the absorbance at 600 nm using a spectrophotometer or an ELISA reader. | 01-07-2016 |
20160001051 | METHOD OF DRUG DELIVERY FOR OVARIAN CANCER - A drug delivery device has been designed to directly deliver an agent to the ovaries through direct contact with the fallopian tubes. The device consists of three main components: a tubular inserter, a cylindrical chamber and a plunger. The device is a single-use applicator designed in a shape similar to a tampon to facilitate its insertion through the vagina and into the uterus. Positioning of the device centrally in the uterus is accomplished through the use of ultrasound. The chamber is inserted into the tubular inserter. Adjusting the length of the chamber inserted into the tubular inserter controls the amount of tubing released from the apertures in the tubular inserter. Ultrasound is used to ensure the proper placement of each tube at the entrance of each fallopian tube. The plunger is inserted into the chamber and adjustment of the plunger controls the amount of the agent released into the tubes. | 01-07-2016 |
20150374474 | SACROCOLPOPEXY/SACROCERVICOPEXY VAGINAL POSITIONING AND MESH RETENTION SYSTEM - A vaginal support device, vaginal positioning system and associated method of treating pelvic prolapse is presented herein. Vaginal support device contains flat superior and inferior surfaces to facilitate affixing of mesh to vagina. Vaginal support device may be used as part of a system in conjunction with a manipulation device to support the vaginal walls. Mesh retention system may also include a holding device and retention mechanism such as a catheter or shaft and corresponding catheter balloon to hold mesh in place. | 12-31-2015 |
20150367114 | METHOD OF DILATING GASTROINTESTINAL STRICTURES USING A TRANS-ENDOSCOPIC HYDRAULIC BALLOON APPARATUS - A trans-endoscopic hydraulic balloon dilation apparatus includes a fluid reservoir containing a hydraulic fluid. A shaft has a lumen in fluid communication with a leading end of the fluid reservoir. A balloon is mounted on the shaft and an opening in the shaft enables hydraulic fluid to flow through the opening into or from the balloon. A piston secured to a leading end of a piston rod is slideably positioned within a lumen of the fluid reservoir. A hub secured to a trailing end of the fluid reservoir is centrally apertured to accommodate the piston rod so that a trailing end of the piston rod is external to the fluid reservoir. Displacement of the piston rod in a trailing-to-leading direction causes expansion of the balloon. Displacement of the piston rod in a leading-to-trailing direction causes deflation of the balloon. The piston can be locked into any position. | 12-24-2015 |
20150366883 | METHOD OF TREATING OVARIAN CANCER USING A PKC INHIBITOR - A method of treating ovarian cancer by administering a PKC inhibitor is presented herein. It was found that administering a PKC inhibitor, such as ACPD or ICA-1, to ovarian cancer cells inhibited cancer cell proliferation. | 12-24-2015 |
20150359240 | CYTOKINE, CHEMOKINE AND GROWTH FACTORS IN DONOR HUMAN MILK - Donor milk has become a standard of care for feeding preterm infants, particularly those with gestational ages of 34 weeks or less, whose mothers are not lactating or not producing sufficient milk quantities. However, prior to distribution, donor milk is required to undergo pasteurization, typically using the Holder method, which is believed to destroy immune proteins in the milk and denature many other proteins. Donor milk has been found to contain concentrations of chemokines, cytokines, and growth factors, evidencing the value of donor milk over formula. In light of the findings, donor milk is supplemented with chemokines, cytokines, and growth factors that are found to be lower in the donor milk as compared to mother's own milk. | 12-17-2015 |
20150357569 | ORGANIC PHOTOVOLTAIC ARRAY AND METHOD OF MANUFACTURE - The fabrication and characterization of large scale inverted organic solar array fabricated using all-spray process is disclosed, consisting of four layers; ITO-Cs | 12-10-2015 |
20150335342 | MINIMALLY INVASIVE LAPAROSCOPIC TISSUE REMOVAL DEVICE - A minimally invasive laparoscopic tissue removal device, namely a morcellator. The device includes, from proximal end to distal end, a handle, handle guard, elongate sheath, and mouth, finally terminating in a safety tip. The elongate sheath and mouth are concentric, such that two elongate, rotating cutting/shredding blades/teeth and one elongate auger feed screw can be positioned along the length of the sheath and mouth. The teeth are opposingly disposed and staggered, such that contact with tissue mass grabs and pulls tissue inwards toward the auger, which transports the tissue proximally toward the outside of the patient's body. A motor unit and gear assembly can be coupled to the teeth and auger to drive rotation of the teeth and auger. A cup assembly can be disposed in overlying relation to the mouth for guiding the tissue mass towards the mouth. Various mechanisms of safely covering the mouth are contemplated as well. | 11-26-2015 |
20150332501 | ANALYSIS-SUITABLE GEOMETRY FROM DISCRETE POINT SETS USING A MESH-FREE METHOD - The present invention includes a method of creating analysis suitable models from discrete point sets. The proposed methodology is completely automated, requiring no human intervention, as compared to traditional mesh-based methods that often require manual input. The present invention is directly applicable to engineering approaches in medicine where the object to be analyzed is described by discrete medical images, such as MRI or CT scans. Moreover, the present invention is useful in any application where the object of interest is created from digitized imaging technology. | 11-19-2015 |
20150327547 | N-ALKYLTHIO BETA-LACTAMS, ALKYL-COENZYME A ASYMMETRIC DISULFIDES, AND ARYL-ALKYL DISULFIDES AS ANTI-BACTERIAL AGENTS - The present invention provides N-alkylthio β-lactams and disulfide compounds (e.g., alkyl-coenzyme A asymmetric disulfides or aryl-alkyl disulfides), compositions containing such compounds, and methods of their use as anti-bacterial agents. | 11-19-2015 |
20150327523 | TRANSGENIC MOUSE MODEL FOR CONDITIONAL FKBP51 EXPRESSION AND RELATED METHODS - The subject invention pertains to transgenic non-human animals comprising a transgenic nucleotide sequence, integrated into the genome of the animals, comprising a nucleotide sequence encoding human FKBP51 operably linked to a tetracycline response element. In some embodiments, the transgenic animal comprises an additional transgenic nucleotide sequence, integrated into the genome of the animal, comprising a nucleotide sequence encoding a tetracycline transactivator (tTA) operably linked to a promoter; wherein the tTA is expressed upon activation of the promoter and binds the tetracycline response element, thereby causing expression of FKBP51. The invention also pertains to methods for screening for agents for the prevention and/or treatment of psychiatric disorders, such as depression. | 11-19-2015 |
20150306068 | COMPOUNDS AND RELATED METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES - Aspects of the invention pertain to chemical compounds, therapeutic compositions, and methods for treating neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau. | 10-29-2015 |
20150305764 | POWER MORCELLATION IN A PROTECTED ENVIRONMENT - A power morcellation system, apparatus, and methodology. Structurally, the device includes a sturdy, pliable (e.g., able to be inserted and retracted through a 10-15 mm morcellator port), distensible, waterproof/watertight retaining bag/pouch/carrier to be deployed into the pelvic cavity of the subject. The device further includes a plurality (e.g., three (3)) of port tube channels extending outwardly from the bag, wherein the interior of each channel is in communication with the interior of the bag. Each channel has an open end (opposite from the end that terminates in the bag) through which a laparoscopic/robotic camera and other instruments (e.g., camera, control instrument) may pass. A smaller tube channel also extends outwardly from the bag and can be suited as an insufflation port channel, among other uses. The bag also includes a large opening surrounded by an elastic drawstring for receiving the specimen to be removed within the bag. | 10-29-2015 |
20150301063 | SALIVARY INFLAMMATORY BIOMARKERS ASSOCIATED WITH GLYCEMIC CONTROL AND ORAL HEALTH - The present invention provides non-invasive diagnostic methods and kits for determining and/or monitoring oral health and glycemic control in subjects with Type 1 diabetes. | 10-22-2015 |
20150284616 | Encapsulation of Thermal Energy Storage Media - In one embodiment, a phase change material is encapsulated by forming a phase change material pellet, coating the pellet with flexible material, heating the coated pellet to melt the phase change material, wherein the phase change materials expands and air within the pellet diffuses out through the flexible material, and cooling the coated pellet to solidify the phase change material. | 10-08-2015 |
20150282836 | LAPAROSCOPIC TOOL WITH OBTURATOR - A laparoscopic device with obturator. The device facilitates extraction of specimens from a female subject's abdominal cavity through the subject's vagina by also facilitating the suturing of a mesh to the anterior and posterior walls of the subject's vagina. The device includes an elongate sheath that has a flat surface on the front, a curved shape on the back, and an inner port opening formed within the flat surface, where the port opening that enables introduction of instruments or removal of specimens from the peritoneal cavity. An internal obturator can be inserted into the sheath to reduce the size of the port opening into the peritoneal cavity, or can be used to close the inner port opening into the peritoneal cavity. The obturator and sheath can be utilized as firm surfaces against which a user can suture a sacrocolpopexy mesh to the anterior and posteriors vaginal walls. | 10-08-2015 |
20150274782 | GAMMA-AAPEPTIDES WITH POTENT AND BROAD-SPECTRUM ANTIMICROBIAL ACTIVITY - The present invention is directed to a novel class of antimicrobial agents called γ-AApeptides. The current invention provides various categories of γ-AApeptides, for example, linear γ-AApeptides, cyclic γ-AApeptides, and lipidated γ-AApeptides. γ-AApeptides of the current invention are designed to exert antimicrobial activity while being stable and non-toxic. γ-AApeptides also do not appear to lead to the development of microbial resistance in treated microorganisms. Thus, the disclosed γ-AApeptides can be used for the treatment of various medical conditions associated with pathogenic microorganisms. | 10-01-2015 |
20150255196 | Magneto-Dielectric Polymer Nanocomposites and Method of Making - In accordance with the present invention, novel superparamagnetic magneto-dielectric polymer nanocomposites are synthesized using a novel process. The tunability of the dielectric/magnetic properties demonstrated by this novel highly-viscous solvent-free polymer nanocomposite that is amenable to building 3D electromagnetic structures/devices by using processes such as 3D printing, compression molding or injection molding, when an external DC magnetic field is applied, exceeds what has been previously reported for magneto-dielectric polymer nanocomposite materials. | 09-10-2015 |
20150251924 | SYSTEMS AND METHODS FOR WATER DESALINATION AND POWER GENERATION - In one embodiment, a water desalination and power generation system includes a power generation subsystem, a water desalination subsystem, and an ejector that links the power generation subsystem and the water desalination subsystem, the ejector being adapted to entrain working fluid steam that has exited the water desalination subsystem into working fluid steam that has exited the power generation subsystem to generate mixed steam that drives the water desalination subsystem. | 09-10-2015 |
20150246340 | Metal-Organic Materials (MOMS) for Polarizable Gas Adsorption and Methods of Using MOMS - Embodiments of the present disclosure provide for multi-component metal-organic materials (MOMs) systems that exhibit permanent porosity and using MOMs to separate components in a gas mixture, methods of separating polarizable gases from a gas mixture, and the like. | 09-03-2015 |
20150238502 | Compositions and Methods for Treating Stroke - Provided herein is a method of treating a subject believed to have suffered a stroke. This method comprises administering to the subject therapeutically effective amount of a composition comprising conivaptan or an active derivative, stereoisomer, pro-drug, or pharmaceutically acceptable salt thereof. | 08-27-2015 |
20150238345 | CUSTOM REDUCTION SPLINT FOR EDENTULOUS PATIENTS - A custom oral splint that is operatively secured to the maxilla and mandible of a subject/patient to assist in reduction and provide maintenance of reduction of maxillary and mandibular fractures in the edentulous or partially edentulous subject/patient. In this difficult patient population, there are very limited options for maxillomandibular fixation, and none provide stable reduction of fractures. The novel device minimizes operative time and equipment, as well as offers the ability to transition the patient from rigid fixation to elastics postoperatively. The novel device is custom-designed for each patient's degree of bone atrophy, ensuring a high quality, and effective product. | 08-27-2015 |
20150234248 | Low-Cost Chromatic Devices - In one embodiment, a chromatic device includes an active layer and an electrolyte layer in contact with the active layer, wherein the active layer has an opaque color that blocks light but changes to a translucent color that transmits light when a metal object is placed in electrical contact with the active layer in the presence of the electrolyte layer. | 08-20-2015 |
20150231172 | TARGETING CANCER WITH METABOLIC THERAPY AND HYPERBARIC OXYGEN - A method of treating cancer using ketogenic diet, while concurrently subjecting the patient to a hyperbaric, oxygen-enriched environment. Optionally, the hyperbaric, oxygen-enriched environment is 100% oxygen at 2.5 ATA absolute. The treatment may further include administering at least 10% ketone supplementation, such as acetoacetate, adenosine monophosphate kinase, 1,3-butanediol, or ketone ester, to the patient. | 08-20-2015 |
20150216432 | Systems and Methods for Diagnosing Cardiovascular Conditions - In one embodiment, a cardiovascular condition is diagnosed by recording a vectorcardiogram for a subject under evaluation, comparing the vectorcardiogram with vectorcardiograms of other subjects, and diagnosing the subject under evaluation based upon the comparison. | 08-06-2015 |
20150209582 | PASSIVE ELECTRIC FIELD FOCUS SYSTEM FOR IN VIVO AND IN VITRO APPLICATIONS - The present invention provides a system and method of directing, focusing, or concentrating electrical charges within a defined electric field so that these charges can be used to exert forces on cells and tissues in vivo and/or cell cultures in vitro. The present invention reduces and/or eliminates the damage at a target site that would normally be caused by an electrode that acts as a current source or sink to accomplish the same task. | 07-30-2015 |
20150190779 | Functionalized Porous Organic Polymers for Olefin/Paraffin Separations - Compositions containing a porous organic polymer and a monovalent metal cation are provided for separation/purification of olefins and paraffins. The compositions can be stable and recyclable. The compositions can contain acidic functional group having monovalent metal cations associated therein. The monovalent metal cations can include Ag(I) and Cu(I), capable of strong cation-pi binding to ethylene and other olefins. The compositions can have a large surface area greater than about 20 m2/g. The compositions can be used to separate/purify mixtures of ethylene and ethane. The compositions can have an ethylene/ethane adsorption selectivity of about 20 to 500 at 296 K. Methods of making the compositions are provided. Methods can include synthesizing the porous organic polymer, grafting acidic functional groups onto the polymer, and cation exchange with a salt or acid of a monovalent metal cation. Methods of olefin/paraffin separation are provided capable of achieving purities over 99%. | 07-09-2015 |
20150174296 | COLLAGEN SCAFFOLDS, MEDICAL IMPLANTS WITH SAME AND METHODS OF USE - The subject invention concerns non-degradable three dimensional porous collagen scaffolds and coatings. These scaffolds can be prepared around sensors for implantation into a body. A specific embodiment of the invention concerns implantable glucose sensors. Sensors comprising a collagen scaffold of the invention have improved biocompatibility by minimizing tissue reactions while stimulating angiogenesis. The subject invention also concerns methods for preparing collagen scaffolds of the invention. The subject invention also concerns sensors that have a collagen scaffold of the invention around the exterior of the sensor. | 06-25-2015 |
20150160223 | METHOD OF PREDICTING NON-RESPONSE TO FIRST LINE CHEMOTHERAPY - The invention provides a method for determining a prognosis of colorectal cancer in a colorectal cancer patient, comprising classifying said patient as having a good prognosis or a poor prognosis using measurements of a plurality of gene products in a cell sample taken from said patient, said gene products being respectively products of at least 1 of the genes listed in Table 1, or respective functional equivalents thereof, wherein said good prognosis predicts a positive response to standard chemotherapy regimens, and said poor prognosis predicts non-responsiveness. Provided herein, the invention includes a gene signature to predict which patients will to benefit from standard colon cancer therapy; alternatively, patients who are classified as non-responders may be more likely to benefit from a novel agent such as a Notch inhibitor. | 06-11-2015 |
20150158013 | METAL-ORGANIC MATERIALS (MOMS) FOR CO2 ADSORPTION AND METHODS OF USING MOMS - Embodiments of the present disclosure provide for metal-organic materials (MOMs), systems that exhibit permanent porosity and using hydrophobic MOMs to separate components in a gas, methods of separating CO | 06-11-2015 |
20150153330 | sAPP-alpha as a Biomarker for Prediction of Inflammatory and Autoimmune-Related Disorders - The subject invention pertains to the use of amyloid precursor protein-alpha (sAPP-α) as a biomarker for prediction of a subject's risk of developing inflammatory and/or autoimmune-related disorders. In addition, the present invention provides methods for optimizing vaccine schedules and compositions, thereby preventing or reducing the risks of vaccine-induced inflammatory and/or autoimmune-related disorders. | 06-04-2015 |
20150141430 | METHOD FOR MODULATING CANONICAL WNT PATHWAY USING FOLATE AND INOSITOL - The canonical Wnt signaling pathway is implicated in wound healing. Administration of a composition having myo-inositol and folic acid upregulates fibronectin and provides the greatest protection in an additive/synergistic manner against adverse Wnt/β-catenin-mediated effects on cell processes relating to cell differentiation, proliferation, and migration that relate to wound healing. | 05-21-2015 |
20150141364 | COMPOSITIONS INCLUDING TRICIRIBINE AND EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR COMPOUNDS OR SALTS THEREOF AND METHODS OF USE THEREOF - This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation. | 05-21-2015 |
20150129838 | BARE QUANTUM DOTS SUPERLATTICE PHOTONIC DEVICES - Manipulation of the passivation ligands of colloidal quantum dots and use in QD electronics. A multi-step electrostatic process is described which creates bare QDs, followed by the formation of QD superlattice via electric and thermal stimulus. Colloidal QDs with original long ligands (i.e. oleic acid) are atomized, and loaded into a special designed tank to be washed, followed by another atomization step before entering the doping station. The final step is the deposition of bare QDs onto substrate and growth of QD superlattice. The method permits the formation of various photonic devices, such as single junction and tandem solar cells based on bare QD superlattice, photodetectors, and LEDs. The devices include a piezoelectric substrate with an electrode, and at least one layer of bare quantum dots comprising group IV-VI elements on the electrode, where the bare quantum dots have been stripped of outer-layer ligands. | 05-14-2015 |
20150093768 | DETECTION OF PROSTATE AND BLADDER CANCER - The present invention relates to a method for the diagnosis, prognosis, and monitoring of cancer, such as early or late stage prostate cancer and bladder cancer, in a subject by detecting Bcl-2 in a biological sample from the subject, preferably a urine or blood sample. Bcl-2 may be measured using an agent that detects or binds to Bcl-2 protein or an agent that detects or binds to encoding nucleic acids, such as antibodies specifically reactive with Bcl-2 protein or a portion thereof. The invention further relates to kits for carrying out the methods of the invention. The invention further relates to a device for the rapid detection of Bcl-2 in a bodily fluid and methods for rapidly measuring Bcl-2 in a bodily fluid. | 04-02-2015 |
20150065995 | INTRALUMINAL OCCLUDING CATHETER - An intraluminal occluding catheter and method for preventing the loss of gas insufflation from a physiological lumen during a medical procedure is presented. The intraluminal occluding catheter is generally comprised of a catheter shaft having a flexible balloon affixed on a distal intraluminal end and a plurality of independent channels extending through the catheter shaft from the external proximal end to the distal intraluminal end. Once inserted into a physiological lumen such as the bowel, the intraluminal occluding catheter controls the loss of insufflation proximally thereby improving the safety and efficiency of TAMIS as well as allowing for more controlled gas exchange to clear smoke or vapor. | 03-05-2015 |
20150051291 | N,N'-DI-1 NAPHTHYLGUANIDINE HCL (NAGH) AND N,N'-DI-P-NITROPHENYLGUANIDINE HCL (NAD) TREATMENT FOR STROKE AT DELAYED TIMEPOINTS - A composition and method of treating stroke by administration of a novel sigma agonist is presented. Twenty-four hours after MCAO, systemic administration of several novel sigma agonists including: Bromo-DTG; Chloro-DTG; N,N′-di-1-Naphthylguanidine hydrochloride (NAGH); N,N′-di-p-Nitrophenylguanidine HCL (NAD) or vehicle were injected subcutaneously daily for 3 days. Rats treated with Bromo-DTG and Chloro-DTG had no significant improvements in any of the motor or cognitive tests while NAGH treated rats showed improved vertical movement and had significantly less motor asymmetry and bias than vehicle treated rats. Sigma receptor agonist NAGH also was found to exert its long-term neuroprotective effects by preserving both gray matter and white matter tracts. Both NAD and NAGH, when administered 24 hours after experimental stroke, reduced neural damage and enhanced behavioral recovery thirty days later which suggests that NAGH and NAD potentially extend the therapeutic window of stroke several fold over the current treatments. | 02-19-2015 |
20150044240 | P53 VACCINES FOR THE TREATMENT OF CANCERS - The present invention relates to immunotherapy methods for treating hyperproliferative disease in humans, particularly to hyperproliferative disease that is refractory to therapy. More specifically, the invention is directed, in one embodiment, to methods for treating a subject with a hyperproliferative disease in which the expression of a self gene is upregulated in therapy-resistant hyperproliferative cells. In another embodiment, an adenoviral expression construct comprising a self gene under the control of a promoter operable in eukaryotic cells is administered to the therapy-resistant hyperproliferative cells. The present invention thus provides immunotherapies for treating therapy-resistant hyperproliferative disease by attenuating the natural immune system's CTL response against hyperproliferative cells or overexpressing mutant p53 antigens, for example. | 02-12-2015 |
20150030609 | DIAGNOSIS AND TREATMENT OF TRAUMATIC BRAIN INJURY - The subject invention identifies CC chemokine ligand 20 (CCL20) as a novel biomarker for diagnosis of traumatic brain injury and/or neurodegeneration in the brain. The subject invention also provides treatment methods for traumatic brain injury and/or neurodegeneration in the brain by modulating systemic and/or brain-specific CCL20-CCR6 signaling. Also provided are uses of CCL20-CCR6 signaling a target for screening for therapeutic agents that are useful for treatment of traumatic brain injury. | 01-29-2015 |
20150030585 | COMPOSITIONS INCLUDING TRICIRIBINE AND ONE OR MORE PLATINUM COMPOUNDS AND METHODS OF USE THEREOF - This application encompasses combination therapies including triciribine and related compounds and one or more platinum compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation. | 01-29-2015 |
20150018276 | METHOD OF TREATMENT OF CANCER USING GUANOSINE 3', 5' CYCLIC MONOPHOSPHATE (CYCLIC GMP) - A method of treating cancer through use of guanosine 3′,5′-cyclic monophosphate (cyclic GMP). Cyclic GMP decreases the number of human breast cancer and prostate adenocarcinoma as well as small-cell and squamous lung cells in culture by 30% (1 μM), 84% (1 mM), 31% (1 μM), and 30% (1 μM), respectively. Cyclic GMP decreases DNA synthesis in human pancreatic, breast, and prostate adenocarcinomas as well as small-cell and squamous cell carcinomas of the lung at its 1 μM concentration by 51%, 54%, 56%, 50% and 52%, respectively. Cyclic GMP when infused for one week decreases the tumor volume of human pancreatic adenocarcinomas in athymic mice 95% compared to untreated animals with human pancreatic adenocarcinomas. | 01-15-2015 |
20140369983 | ISCHEMIC TISSUE CELL THERAPY - The present invention is directed to compositions and methods for treatment of ischemic diseases and conditions, particularly myocardial, CNS/brain and limb ischemia. More particularly, the present invention provides methods of treating disorders by administering monocytes obtained from blood, including umbilical cord blood, peripheral blood, or bone marrow to an individual in need of treatment, wherein the drug is administered to the individual at a time point specifically determined to provide therapeutic efficacy. In one embodiment, the cells are for injection into ischemic myocardium for the treatment of angina. | 12-18-2014 |
20140367258 | SYSTEM AND METHOD FOR ELECTROWETTING ACTUATION UTILIZING DIODES - An electrowetting system and method for the movement of a droplet across the surface of a substrate, utilizing an applied voltage. The actuation of the droplet is achieved by introducing a diode into the idealized electrical circuit of the electrowetting system. The diode is in parallel with a capacitor (dielectric) and effectively shorts the droplet on the side of a lower potential electrode so that the entire voltage drop is across the dielectric over the higher potential electrode. This difference in potential creates an energy imbalance that is effective in moving the droplet towards the higher potential electrode. If the voltage polarity is reversed, the direction of actuation will also be reversed. | 12-18-2014 |
20140356955 | FERROMAGNETIC CELL AND TISSUE CULTURE MICROCARRIERS - A porous, collagen coated, ferromagnetic cell culture microcarrier, which is suitable for in vitro cell and tissue culture and which facilitates 3D multicellular construct generation. Also provided is a method for creating batches of microcarriers which have inserted within them magnetite (Fe3O4) in the presence of collagen, thus creating a microcarrier which becomes magnetic in nature when placed in a the presence of a magnetic field and which facilitates cellular adherence (via the collagen coating) for 3D construct development. | 12-04-2014 |
20140350105 | COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS - Beta-hydroxybutyrate mineral salts in combination with medium chain fatty acids or an ester thereof such as medium chain triglycerides were used to induce ketosis, achieving blood ketone levels of (2-7 mmol/L), with or without dietary restriction. The combination results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance in a short period of time. Further, use of these supplements to achieve ketosis yields a significant elevation of blood ketones and reduction of blood glucose levels. Use of these substances does not adversely affect lipid profiles. By initiating rapid ketosis and accelerating the rate of ketoadaptation, this invention is useful for the avoidance of glucose withdrawal symptoms commonly experienced by individuals initiating a ketogenic diet, and minimizes the loss of lean body mass during dietary restriction. | 11-27-2014 |
20140343120 | METHODS AND COMPOSITIONS FOR REDUCING ACTIVITY OF THE ATRIAL NATRIURETIC PEPTIDE RECEPTOR AND FOR TREATMENT OF DISEASES - Methods, compositions and devices are provided by the present invention for reducing activity of a natriuretic peptide receptor and other signals. Therapeutic treatments are provided by use of polynucleotides encoding a natriuretic peptide or by regulating the expression of natriuretic peptide receptor, such as NPRA and NPRC, or combinations of these therapies. Routes used for delivering polynucleotides encoding a natriuretic peptide, or, for example, siRNA that down regulates natriuretic peptide receptor include subcutaneous injection, oral gavage, transdermal and intranasal delivery routes. Compositions can include chitosan, chitosan derivatives, and chitosan derivative and a lipid. Transdermal delivery can use a transdermal cream. Intranasal delivery can use a dropper or an aspirator for delivery of a mist. Oral gavage delivers equivalent to oral delivery. Delivery permits cell and tissue specific targeting of gene therapies resulting in expression of a natriuretic peptide or down regulation of natriuretic peptide receptor. A variety of cancers, asthma and viral diseases can be treated therapeutically using the methods and compositions of the present invention. | 11-20-2014 |
20140329900 | SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY - The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S31-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis. The invention further includes an in-vitro screening test for the presence of malignant cells in a mammalian tissue; a method of identifying inhibitors of constitutive Stat3 activation, Stat3-DNA binding, Stat5-DNA binding, and/or Stat3 dimerization; and a method of identifying anti-cancer agents. | 11-06-2014 |
20140329791 | COMPOUNDS AND RELATED METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES - Aspects of the invention pertain to chemical compounds, therapeutic compositions, and methods for treating neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau. | 11-06-2014 |
20140316570 | SYSTEMS AND METHODS FOR COMMUNICATING ROBOT INTENTIONS TO HUMAN BEINGS - In one embodiment, communicating robot intentions to human beings involves determining movements that a robot will make to complete a task, visually communicating a long-term intention of the robot that provides an indication of the movements the robot will make in completing the task, and visually communicating a short-tem intention of the robot that provides an indication of a movement of the robot will make within the next few seconds in working toward completing the task. | 10-23-2014 |
20140303111 | COMPOSITIONS INCLUDING TRICIRIBINE AND TAXANES AND METHODS OF USE THEREOF - This application relates to combination therapies including triciribine and related compounds and taxanes and compositions with reduced toxicity thr the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation. | 10-09-2014 |
20140303110 | EFFECTIVE TREATMENT OF TUMORS AND CANCER WITH TRICIRIBINE AND RELATED COMPOUNDS - The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat tumors and cancer by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug. | 10-09-2014 |
20140302406 | Electrode Mesh Galvanic Cells - The present invention is directed to the fabrication of thin aluminum anode batteries using a highly reproducible process that enables high volume manufacturing of the galvanic cells. A thin aluminum anode galvanic cell having a meshed structure is provided which includes a catalytic metal layer positioned on a patterned silicon substrate, an etched dielectric layer positioned to cover the catalytic metal layer, the catalytic metal layer serving as an etch stop for the etched dielectric layer and an etched aluminum layer positioned to cover the dielectric layer, the dielectric layer serving as an etch stop for the etched aluminum layer. | 10-09-2014 |
20140302011 | COMPOSITIONS INCLUDING TRICIRIBINE AND TRASTUZUMAB AND METHODS OF USE THEREOF - This application relates to combination therapies including triciribine and related compounds and trastuzumab or a salt thereof and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation. | 10-09-2014 |
20140296128 | MATERIALS AND METHODS FOR TREATMENT OF CANCER AND IDENTIFICATION OF ANTI-CANCER COMPOUNDS - The subject invention pertains to the treatment of tumors and cancerous tissues and the prevention of tumorigenesis and malignant transformation through the modulation of JAK/STAT3 intracellular signaling. The subject invention concerns pharmaceutical compositions containing cucurbitacin I, or a pharmaceutically acceptable salt or analog thereof. Another aspect of the invention concerns methods of inhibiting the growth of a tumor by administering a cucurbitacin I, or a pharmaceutically acceptable salt or analog thereof, to a patient, wherein the tumor is characterized by the constitutive activation of the JAK/STAT3 intracellular signaling pathway. The present invention further pertains to methods of moderating the JAK and/or STAT3 signaling pathways in vitro or in vivo using cucurbitacin I, or a pharmaceutically acceptable salt or analog thereof. Another aspect of the present invention concerns a method for screening candidate compounds for JAK and/or STAT3 inhibition and anti-tumor activity. | 10-02-2014 |
20140288486 | TRANSVAGINAL SPECIMEN EXTRACTION DEVICE - In laparoscopic surgery, small (5-12 mm diameter) incisions are made in the abdominal wall through which instruments dissect and remove specimens that may be several centimeters in diameter. Removal of the sample typically requires either enlarging these incisions or morcellating the sample to pass through the sub-centimeter ports. The laparoscopic device permits extraction of the sample to be removed in a female using the vagina, which has sufficient elasticity to accommodate removal of large specimens. The posterior portion of the vagina communicates to the abdomen through a few tissue layers, and is distant from vital anatomic structures. Utilizing the vagina is optimal due to its ease of access to the abdomen and repair, minimal scarring and post-operative pain, and faster recovery following surgery. A deployable collection bag is housed in a sheath, which is deployed into the vagina or abdominal cavity to extract a large (multiple-centimeter) specimen(s) through the vagina. Optional insufflation system and inflatable balloon to maintain pneumoperiotoneum may be used to reduce the number of laparoscopic ports required. | 09-25-2014 |
20140274883 | NOVEL ANTIVIRAL COMPOUNDS FROM MARINE EXTRACTS - The subject invention pertains to novel biologically active extracts from marine algae and to biologically active fractions and components of these extracts. These extracts have been shown to possess antiviral properties. Pharmaceutical compositions comprising these extracts, or comprising biologically active fractions or components of these extracts, could be used in the treatment of viral diseases including influenza. | 09-18-2014 |
20140258356 | COLUMN AND CONSTRAINT GENERATION METHOD FOR OPTIMAL STRATEGIES - Optimization processes, which are parameter driven for solving interdiction problems, for example, power grid interdiction problems, are provided. An algorithm of the subject invention can include column-and-constraint generation and can be used to solve a set of system interdiction, vulnerability analysis, and reliability based design problems, including a power grid vulnerability analysis problem and an edge-interdiction minimum dominating set problem. An algorithm can be provided on a computer-readable medium, a computer, a portable computing device, or other machine. | 09-11-2014 |
20140255337 | METHODS OF TREATING COGNITIVE IMPAIRMENT - The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment. | 09-11-2014 |
20140242193 | LITHIUM COMPOSITIONS - 2:1 cocrystals of amino acids and Li+ salts crystallize from hot water to afford water stable cationic networks based upon tetrahedral lithium cations: bilayered square grids, a lithium zeolitic metal-organic material (LiZMOM) and several lithium diamondoid metal-organic materials (LiDMOMs). The compositions may be used as a pharmaceutical for the treatment of suicidality and other disorders that require lithium to penetrate the blood brain barrier and exert therapeutic effects in the CNS. Advantageously, the novel cocrystal forms described herein may be used to lower the oral dose required to achieve therapeutic concentrations of lithium in the brain, thus reducing the peripheral toxicity and potentially broadening the therapeutic index in comparison to conventional lithium forms. | 08-28-2014 |
20140235659 | DELTA-TOCOTRIENOL TREATMENT AND PREVENTION OF PANCREATIC CANCER - Methods are disclosed for treating neoplastic disorders, such as pancreatic cancer, using tocotrienols; namely, gamma-tocotrienol and delta tocotrienol. The antitumorogenic effects of these compounds are shown both in vitro and in vivo using several human pancreatic cancer cell lines and MIA-PACA2 human pancreatic cancer cells xenografted in nude mice. Also disclosed are methods of testing the efficacy of potential chemotherapeutic agents by measuring their effect on surrogate endpoint biomarkers, such as Ki-67 and p27. Associated compounds are also disclosed. | 08-21-2014 |
20140235565 | N-ALKYLTHIO BETA-LACTAMS, ALKYL-COENZYME A ASYMMETRIC DISULFIDES, AND ARYL-ALKYL DISULFIDES AS ANTI-BACTERIAL AGENTS - The present invention provides N-alkylthio β-lactams and disulfide compounds (e.g., alkyl-coenzyme A asymmetric disulfides or aryl-alkyl disulfides), compositions containing such compounds, and methods of their use as anti-bacterial agents. | 08-21-2014 |
20140234401 | METHOD OF TREATING INFLAMMATION USING HUMAN IMMUNOSUPPRESSIVE PROTEIN - A method of treating inflammation by administering a therapeutically effective amount of a human immunosuppressant protein (HISP) to a subject is presented. The inventors have discovered a novel immunosuppressive protein purified from the supernatant of hNT cell culture. The immunosuppressant protein has a molecular weight of about 40-100 kDa, an isoelectric point of about 4.4, a net ionic charge and is capable of suppressing T-cell activation, T-cell proliferation and the production of IL-2. This protein can be used in treating inflammation, preventing graft rejection after transplantation, treating autoimmune diseases and suppressing allergic responses as well as other uses. | 08-21-2014 |
20140221658 | INHIBITION OF CELL PROLIFERATION - The disclosed modulators of Rb:Raf-1 interactions are potent, selective disruptors of Rb:Raf-1 binding, with IC | 08-07-2014 |
20140213802 | (-)-Epigallocatechin Gallate Derivatives for Inhibiting Proteasome - A method of reducing tumor cell growth, the method including administering an effective amount of a compound having the formula: | 07-31-2014 |
20140213604 | PROTEIN KINASE C AS A TARGET FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS - The subject invention concerns a method of inhibiting respiratory syncytial virus (RSV) infection in a patient by decreasing the endogenous protein kinase C (PKC) activity within the patient. Preferably, the preventative and therapeutic methods of the present invention involve administration of a PKC inhibitor. The present inventor has determined that decreasing normal endogenous PKC activity is inhibitory to RSV infection of human cells. The subject invention also pertains to pharmaceutical compositions containing a PKC inhibitor and a pharmaceutically acceptable carrier. | 07-31-2014 |
20140209564 | Method for the Fabrication of Electrolyte Cavities Using Surface Micromachining - The present invention is directed to the fabrication of thin aluminum anode batteries using a highly reproducible process that enables high volume manufacturing of the galvanic cells. A method of fabricating a thin aluminum anode galvanic cell is provided, the method including, depositing a layer of catalytic metal on a surface of a first substrate, depositing and patterning a benzocyclobutene layer to form a reservoir having four sidewalls of benzocyclobutene on the surface of the catalytic layer, depositing a layer of aluminum on a surface of a second substrate and bonding the first substrate to the second substrate to form a galvanic cell bounded by the catalytic metal layer and the aluminum layer and separated by the reservoir walls of benzocyclobutene, the second substrate positioned in overlying relation to contact the four sidewalls of the reservoir with the aluminum layer facing the catalytic layer. | 07-31-2014 |
20140205570 | RECOMBINANT ADENO-ASSOCIATED VIRUS-MEDIATED EXPRESSION OF FRACTALKINE FOR TREATMENT OF NEUROINFLAMMATORY AND NEURODEGENERATIVE DISEASES - The subject invention pertains to the use of fractalkine (FKN, CX3CL1) and its receptor CX3CR1 for treatment of neuroinflammation and/or neurodegeneration. In one embodiment, the present invention provides a method for treatment of neuroinflammation and/or neurodegenerative diseases, comprising: administering, to cells of a subject in need of such treatment, an adeno-associated virus that comprises a functional fractalkine gene operably linked to transcriptional control elements. In one embodiment, the subject invention is used to treat or ameliorate Parkinson's disease. The present invention can also be used to treat or ameliorate neuroinflammatory and/or neurodegenerative diseases including, but not limited to, Alzheimer's disease, epilepsy, aging, and traumatic brain injury. | 07-24-2014 |
20140197355 | METHOD OF ENCAPSULATING A PHASE CHANGE MATERIAL WITH A METAL OXIDE - Storage systems based on latent heat storage have high-energy storage density, which reduces the footprint of the system and the cost. However, phase change materials (PCMs), such as NaNO | 07-17-2014 |
20140194834 | Auto-Regulation System for Intraocular Pressure - A device and system for controlling pressure via fluid exchange in the body is presented. The device and system may be used to control intraocular eye pressure. The system is comprised of four main components: a cannula, a sensor, a controller and a pump. The system works to engage in a fluid exchange which slowly increases/decreases intraocular pressure until a desired level is reached. Once the desired level is reached, the intraocular pressure is held steady and any external pressure perturbations are removed. | 07-10-2014 |
20140194719 | Long-Term Implantable Silicon Carbide Neural Interface Device Using the Electrical Field Effect - Field effect devices, such as capacitors and field effect transistors, are used to interact with neurons. Cubic silicon carbide is biocompatible with the neuronal environment and has the chemical and physical resilience required to withstand the body environment and does not produce toxic byproducts. It is used as a basis for generating a biocompatible semiconductor field effect device that interacts with the brain for long periods of time. The device signals capacitively and receives signals using field effect transistors. These signals can be used to drive very complicated systems such as multiple degree of freedom limb prosthetics, sensory replacements, and may additionally assist in therapies for diseases like Parkinson's disease. | 07-10-2014 |
20140194495 | CYTOTOXIN COMPOUNDS AND METHODS OF ISOLATION - The present invention concerns groups of compounds derived from tunicates of the | 07-10-2014 |
20140190898 | Cactus Mucilage and Ferric Ions for the Removal of Arsenate (As(V)) from Water - Potable drinking water is plagued with widespread arsenic contamination, particularly in developing communities. Ferric ions were introduced to interact with arsenate based on the strong affinity of arsenate for ferric hydroxides, followed by mucilage addition. The mucilage coagulated and flocculated the ferric-arsenate complex and formed visible flocs that settled at the bottom of the tubes. The system showed 75-96% arsenate removal in 1 hour, while longer retention times showed 100% removal. The role of the mucilage was demonstrated by untreated solutions showing no concentration difference and remaining stable for more than 15 days. This mucilage-based technology has the potential to be a relatively inexpensive, environmentally sustainable alternative to synthetic polymer flocculants for removing arsenic from drinking water. | 07-10-2014 |
20140186316 | METHODS AND COMPOSITIONS FOR TREATMENT OF TRAUMATIC BRAIN INJURY AND FOR MODULATION OF MIGRATION OF NEUROGENIC CELLS - Disclosed herein are methods for the treatment of traumatic brain injury by transplantation of cells descended from marrow adherent stem cells that express an exogenous Notch intracellular domain. The transplanted cells form a pathway along which endogenous neurogenic cells proliferate and migrate from the subventricular zone to the site of injury. | 07-03-2014 |
20140179979 | THERAPEUTIC AGENT APPLICATORS AND METHODS OF USING THE SAME - The present application relates to applicators and methods for administering therapeutic agents to cancerous tissue. The applicators can be used to deliver radiation and additional therapeutic agents to cancerous tissue located in a subject. | 06-26-2014 |
20140171921 | URETHRAL CATHETER ASSEMBLY WITH A GUIDE WIRE - A urethral catheter assembly utilizing a removable guide wire for navigating the catheter through a patient's urethral lumen during the insertion procedure. The guide wire being very flexible and having a low coefficient of friction, thus reducing the likelihood of injuring or puncturing the urethra during insertion. The guide wire extends beyond the distal end of the catheter assembly to ensure that the flexible tip of the guide wire is the first contact point between the catheter assembly and the urethral lumen. In one embodiment, the guide wire extends beyond the proximal end of the catheter assembly and is adapted to be handled by a medical doctor to manually maneuver the guide wire through the urethra. | 06-19-2014 |
20140162989 | MULTIPLE-COMPONENT SOLID PHASES CONTAINING AT LEAST ONE ACTIVE PHARMACEUTICAL INGREDIENT - The subject invention concerns a method for identifying complementary chemical functionalities to form a desired supramolecular synthon. The subject invention also pertains to binary phase compositions comprising one or more pharmaceutical entities and methods for producing such compositions. | 06-12-2014 |
20140142047 | POST PROTEIN HYDROLYSIS REMOVAL OF A POTENT RIBONUCLEASE INHIBITOR AND THE ENZYMATIC CAPTURE OF DNA - The present invention concerns compositions and methods of extracting infectious pathogens from a volume of blood. In one embodiment, the method includes the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The present invention also concerns materials and methods for removing aurintricarboxylic acid (ATA) from a sample. | 05-22-2014 |
20140132286 | NONCONTACT DETERMINATION OF INTERFACE TRAP DENSITY FOR SEMICONDUCTOR-DIELECTRIC INTERFACE STRUCTURES - Embodiments of the subject method and apparatus relate to a sequence of noncontact Corona-Kelvin Metrology, C-KM, that allows the determination and monitoring of interface properties in dielectric/wide band gap semiconductor structures. The technique involves the incremental application of precise and measured quantities of corona charge, Q | 05-15-2014 |
20140124021 | MICROSTRUCTURED CRYSTALLINE DEVICE IN CONFINED SPACE, A DYE-SENSITIZED SOLAR CELL, AND METHOD OF PREPARATION THEREOF - A method of forming an ordered nanorods array in a confined space is used to form a high surface area device where an ensemble of parallel trenches has micrometer dimensions for the width and depth of the trenches, which are decorated with crystalline nanowires radiating from the sidewalls and bases of the trenches. The high surface area device is formed by depositing a conformal crystalline seed coating in the trenches, forming microchannels from these trenches by placing a barrier layer on the open surface of the trenches, contacting the conformal coating with a crystal precursor solution that is caused to flow through the microchannels. In an embodiment, a very high surface area electrode is constructed with ZnO nanowires radiating from the sidewalls and base of trenches formed on a silicon substrate. The device can be a dye-sensitized solar cell. | 05-08-2014 |
20140103247 | Magneto-Dielectric Polymer Nanocomposites and Method of Making - In accordance with the present invention, novel superparamagnetic magneto-dielectric polymer nanocomposites are synthesized using a novel process. The tunability of the dielectric/magnetic properties demonstrated by this novel polymer nanocomposite, when an external DC magnetic field is applied, exceeds what has been previously reported for magneto-dielectric polymer nanocomposite materials. | 04-17-2014 |
20140099286 | CELL THERAPY FOR CHRONIC STROKE - A method of treating stroke in a patient who has undergone a stroke comprising administering at least 2 million suitable neuronal cells in at least one brain area involved in the stroke. The method comprises the step of using a twist drill or a burr to form a hole in the skull through which the cells could be administered. Exemplary cells are hNT neuronal cells, HCN-1 cells, fetal pig cells, neural crest cells, neural stem cells, or a combination thereof. Also disclosed herein is a pharmaceutical composition of 95% pure hNT neuronal cells, which composition further includes a vial containing PBS and human neuronal cells. This vial is provided in a container with liquid nitrogen, whereby the composition is frozen and maintained at −170° C. before use. Also disclosed are methods of improving speech, cognitive, sensory, and motor function in a person who has experienced brain damage which interferes with function by administering a sterile composition of a sufficient number of neuronal cells or neural stem cells to the damaged area. Also disclosed is a method of replacing central nervous cells lost to neurodegenerative disease, trauma, ischemia or poisoning. | 04-10-2014 |
20140094467 | METHOD AND COMPOSITION FOR MODULATING CANONICAL WNT PATHWAY USING FOLATE AND INOSITOL - The canonical Wnt signaling pathway is implicated in many disorders including neural tube defects, limb malformations, and heart defects, developmental disorders associated with alcohol exposure (fetal alcohol syndrome) or exposure to bipolar medications (i.e. lithium), wound healing, and Alzheimer's disease. Elevated plasma homocysteine (HCy), which results from folate (folic acid, FA) deficiency, the mood-stabilizing drug lithium (Li), and alcohol (ethanol) are linked to the induction of human congenital heart and neural tube defects. FA supplementation ameliorates the observed developmental errors in the Li-HCy, or alcohol-exposed mouse embryos and normalized heart function. Li, HCy or Wnt3A suppress Wnt-modulated Hex and Islet-1 expression. FA protects from the gene misexpression that is induced by all three factors. Administration of myo-inositol with FA synergistically enhances the protective effect. | 04-03-2014 |
20140093944 | POST PROTEIN HYDROLYSIS REMOVAL OF A POTENT RIBONUCLEASE INHIBITOR AND THE ENZYMATIC CAPTURE OF DNA - The present invention concerns compositions and methods of extracting infectious pathogens from a volume of blood. In one embodiment, the method includes the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The present invention also concerns materials and methods for removing aurintricarboxylic acid (ATA) from a sample. | 04-03-2014 |
20140093933 | MICROBIAL CELL AND PARTICLE SELECTION SYSTEM AND METHOD OF USE - The invention comprises two key components: dielectrophoresis (DEP) and reversible binding surfaces. DEP has become an important tool for trapping dielectric particles. Moreover, DEP can manipulate cell movement as dictated by the intrinsic dielectric constant of the cell without modification. DEP therefore provides a mechanism by which to force targets in a flow channel to a reversible binding surface. By building selectivity into the binding surface, the capacity to choose which targets can be held after the dielectric field is turned off, providing a separation strategy that does not suffer from fouling issues, as large foulants can freely pass over the surface through the flow channel. | 04-03-2014 |
20140087467 | FERROMAGNETIC CELL AND TISSUE CULTURE MICROCARRIERS - A porous, collagen coated, ferromagnetic cell culture microcarrier, which is suitable for in vitro cell and tissue culture and which facilitates 3D multicellular construct generation. Also provided is a method for creating batches of microcarriers which have inserted within them magnetite (Fe3O4) in the presence of collagen, thus creating a microcarrier which becomes magnetic in nature when placed in a the presence of a magnetic field and which facilitates cellular adherence (via the collagen coating) for 3D construct development. | 03-27-2014 |
20140087447 | Cell Modeling of Heme Deficiency using Ferrochelatase Mutations - Provided herein, is a means for development of ferrochelatase variants with improved tolerance towards N-methyl protoporphyrin. Also disclosed are cell assay systems utilizing the variants, as the variants would confer resistance to N-methyl protoporphyrin inhibition and thereby keep heme synthesis uninterrupted. The variants contain loop mutations that affect the NMPP-ferrochelatase interaction, and different degrees of NMPP tolerance are obtained with the introduction of loop mutations in wild-type ferrochelatase. Also disclosed is kinetic mechanism of inhibition of ferrochelatase by NMPP, using the disclosed variants whose mutations in the “porphyrin-interacting loop” motif weakened the potency of NMPP as an inhibitor. | 03-27-2014 |
20140087440 | MAGNETIC THREE-DIMENSIONAL CELL CULTURE APPARATUS AND METHOD - A culture apparatus and method for growing cells and tissue in a three-dimensional configuration harnesses magnetic, paramagnetic, ferromagnetic and diamagnetic forces. The cells or tissue are grown with magnetized core particles and are suspended via magnetic forces in a native, non-restricted, three-dimensional configuration while being maintained in a normal gravity (1 g) growth environment in the absence of rotational alteration of the gravity vector. | 03-27-2014 |
20140082932 | Method for the Fabrication of Electrolyte Cavities Using Bulk Micro-Machining - The present invention is directed to the fabrication of thin aluminum anode batteries using a highly reproducible process that enables high volume manufacturing of the galvanic cells. A method of fabricating a thin aluminum anode galvanic cell is provided, the method comprising, forming a recess in the silicon wafer, the recess having no more than three sidewalls, depositing a catalytic metal layer on a bottom surface of the recess, positioning a double-side sticky tape layer having a bottom side positioned to contact the no more than three sidewalls of the recess and positioning an aluminum foil layer to contact a top side of the double-side sticky tape layer and in overlying relation to the recess, thereby forming the galvanic cell. | 03-27-2014 |
20140080762 | HYD1 PEPTIDES FOR RELAPSED CANCER - The subject invention pertains to compositions and methods for treatment of malignancies and inhibiting the growth of cancer cells, such as multiple myeloma and other hematologic malignancies, using HYD1 peptides. Other aspects of the invention are directed to methods for selection of agents useful in the treatment of malignancies and inhibiting the growth of cancer cells. Further aspects of the invention include methods for determining whether a cancer is sensitive or resistant to treatment with HYD1 peptides based on the presence of certain biomarkers, such as α4 integrin and CD44 expression. | 03-20-2014 |
20140074135 | SMALL DIAMETER LAPAROSCOPIC TOOL HAVING RELEASABLE TIP - A laparoscopy tool includes a sheath and a control wire slideably disposed within a lumen of the sheath. The sheath has a diameter of less than 1.6 mm and is introduced through an abdominal incision. A handle axially displaces the control wire within the lumen and operates a conventional tip with wire-controlled opposing jaws that is introduced through the umbilicus and has a bore formed in its trailing end. A first set of blades in the bore engage grooves formed in the leading end of the control wire and a second set of blades engages the sheath to prevent sheath retraction. A cam displaces the second set of blades away from the sheath for sheath introduction and removal, and toward the sheath to prevent sheath retraction. The tip is removed through the umbilicus and the tool is removed through the abdominal incision when the surgery is completed. | 03-13-2014 |
20140073704 | COLLAGEN SCAFFOLDS, MEDICAL IMPLANTS WITH SAME AND METHODS OF USE - The subject invention concerns non-degradable three dimensional porous collagen scaffolds and coatings. These scaffolds can be prepared around sensors for implantation into a body. A specific embodiment of the invention concerns implantable glucose sensors. Sensors comprising a collagen scaffold of the invention have improved biocompatibility by minimizing tissue reactions while stimulating angiogenesis. The subject invention also concerns methods for preparing collagen scaffolds of the invention. The subject invention also concerns sensors that have a collagen scaffold of the invention around the exterior of the sensor. | 03-13-2014 |
20140073693 | USE OF KETONE ESTERS FOR PREVENTION OF CNS OXYGEN TOXICITY - The present invention demonstrates the therapeutic use of ketone esters for seizure disorders, Alzheimer's disease and malignant brain cancer, which are associated with metabolic dysregulation. The administration of ketone esters resulted therapeutic ketosis and neuroprotection against seizures resulting from CNS oxygen toxicity. Supplemental ketones were also found to reduce superoxide production in cultured cortex neurons exposed to hyperbaric oxygen and Aβ-42, and to decrease proliferation and viability in U87 glioma cells. These observations support the therapeutic effect of ketones for seizure disorders, Alzheimer's disease and malignant brain cancer. The ketone esters may be derived from acetoacetate and can include R,S-1,3-butanediol acetoacetate monoester, R,S-1,3-butanediol acetoacetate diester, or a combination of the two. | 03-13-2014 |
20140072654 | CANCER WITH METABOLIC THERAPY AND HYPERBARIC OXYGEN - The present invention demonstrates the therapeutic use of ketone esters for seizure disorders, Alzheimer's disease malignant brain cancer, and other cancers, which are associated with metabolic dysregulation. The administration of a ketogenic diet, such as ketone esters, while concurrently subjecting the patient to a hyperbaric, oxygen-enriched environment resulted in therapeutic ketosis. Optionally, the hyperbaric, oxygen-enriched environment is 100% oxygen at 2.5 ATA absolute. The ketone esters may be derived from acetoacetate and can include R,S-1,3-butanediol acetoacetate monoester, R,S-1,3-butanediol acetoacetate diester, or a combination of the two. The treatment may further include administering at least 10% ketone supplementation, such as acetoacetate, adenosine monophosphate kinase, 1,3-butanediol, or ketone ester, to the patient. | 03-13-2014 |
20140071446 | Dual-Gas Microcavity Raman Sensor and Method of Use - In accordance with the present invention, a dual-gas Raman sensor is provided that is based on an enhanced spontaneous dual emission as a result of cavity quantum electrodynamic effects. The dual-gas sensor includes a first reflector that exhibits a high reflectivity near the Raman shifted emission for the first species of interest and a moderate reflectivity near the Raman shifted emission for the second species of interest and a second reflector that exhibits a high reflectivity near the Raman shifted emission for the first species of interest and a moderate reflectivity near the Raman shifted emission for the second species of interest, allowing for the simultaneous measurement of the density of both the first species of interest and the second species of interest. | 03-13-2014 |
20140069296 | ANTI-FOULING BIO-HYDROGEL COMPOSITION - The invention comprises a biological hydrogel that is chemically stabilized with non-covalent or covalent cross-links. The biological hydrogel is used to coat surfaces of materials for submersion in marine water. Molecular dissolution at the marine water-hydrogel surface prevents attachment of fouling organisms. The rate of dissolution can be controlled by both the concentration of the biopolymer in the hydrogel and the nature and concentration of cross-linker used. Additional components, either molecular or particulate, can be added to the biological hydrogel before or after cross-linking for enhanced properties. | 03-13-2014 |
20140067023 | OPTICAL NEURON STIMULATION PROSTHETIC USING SILICON CARBIDE - The microfabricated prosthetic device uses local, direct, and wavelength-specific optical stimulation to achieve an action potential from a single or small group of neurons within the central nervous system (CNS). The device is biocompatible, mechanically flexible, and optically transparent. The device can also use integrated electrodes for additional input/output (IO) locations, signal verification, feedback, wireless communication, and characterization of the electrochemically-evoked potential received from the activated neuron. The purpose of the device is to act as a neural interface prosthetic. The prosthetic is designed as the central component of a brain machine interface (BMI). | 03-06-2014 |
20140065208 | PROSTATE CARCINOGENESIS PREDICTOR - A method of detecting prostate tumorigenesis in a subject, the method including the steps of (a) obtaining a sample from the prostate of the human subject, (b) detecting quantitatively or semi-quantitatively in the sample a level of expression for PKC-ι and (c) comparing the expression level in (b) to a level of expression in a normal control, wherein overexpression of PKC-ι, with respect to the control, indicates the presence of prostate cancer in the subject. The present invention is based upon the discovery that PKC-ι levels are elevated during prostate tumorigenesis. Furthermore, the proliferation rate of the tumor correlates with the level of PKC-ι. The invention also provides methods of treating prostate cancer by administering to the subject a compound that inhibits the expression of PKC-ι. The compound can be a small interfering RNA (siRNA) molecule. | 03-06-2014 |
20140065133 | JAK/STAT INHIBITORS AND MAPK/ERK INHIBITORS FOR RSV INFECTION - The present invention concerns a method for treating or reducing the likelihood of developing a respiratory syncytial virus (RSV) infection in a subject by administering an effective amount of an inhibitor of the janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway or the mitogen-activated kinase (MAPK)/extracellular signal-regulated kinase (ERK1/2) signaling pathway to the subject. Another aspect of the invention concerns a pharmaceutical composition that includes an inhibitor of JAK/STAT or MAPK/ERK signaling to the subject; and a pharmaceutically acceptable carrier. Another aspect of the invention concerns a method for identifying agents useful for treating or reducing the likelihood of developing an RSV infection | 03-06-2014 |
20140057249 | JAK/STAT INHIBITORS AND MAPK/ERK INHIBITORS FOR RSV INFECTION - The present invention concerns a method for treating or reducing the likelihood of developing a respiratory syncytial virus (RSV) infection in a subject by administering an effective amount of an inhibitor of the janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway or the mitogen-activated kinase (MAPK)/extracellular signal-regulated kinase (ERK1/2) signaling pathway to the subject. Another aspect of the invention concerns a pharmaceutical composition that includes an inhibitor of JAK/STAT or MAPK/ERK signaling to the subject; and a pharmaceutically acceptable carrier. Another aspect of the invention concerns a method for identifying agents useful for treating or reducing the likelihood of developing an RSV infection | 02-27-2014 |
20140057048 | METHOD OF MAKING IONIC LIQUID MEDIATED SOL-GEL SORBENTS - Ionic liquid (IL)-mediated sol-gel hybrid organic-inorganic materials present enormous potential for effective use in analytical microextraction. One obstacle to materializing this prospect arises from high viscosity of ILs significantly slowing down sol-gel reactions. A method was developed which provides phosphonium-based, pyridinium-based, and imidazolium-based IL-mediated advanced sol-gel organic-inorganic hybrid materials for capillary microextraction. Scanning electron microscopy results demonstrate that ILs can serve as porogenic agents in sol-gel reactions. IL-mediated sol-gel coatings prepared with silanol-terminated polymers provided up to 28 times higher extractions compared to analogous sol-gel coatings prepared without any IL in the sol solution. This study shows that IL-generated porous morphology alone is not enough to provide effective extraction media: careful choice of the organic polymer and the precursor with close sol-gel reactivity must be made to ensure effective chemical bonding of the organic polymer to the created sol-gel material to be able to provide the desired sorbent characteristics. | 02-27-2014 |
20140056931 | GENETIC ADJUVANTS FOR IMMUNOTHERAPY - The present invention pertains to methods and pharmaceutical compositions for modulating an immune response. The method of the present invention involves administration of an effective amount of nucleic acid molecules encoding interleukin-12 (IL-12), interferon-gamma (IFN-γ), or a combination thereof, to a patient in need of such treatment. The pharmaceutical compositions of the invention contain nucleic acid molecules encoding IL-12 and/or IFN-γ and an operably-linked promoter sequence. In another aspect, the present invention concerns expression vectors containing a nucleotide sequence encoding IL-12 and IFN-γ, and an operably-linked promoter sequence. In another aspect, the present invention concerns cells genetically modified with a nucleotide sequence encoding IL-12 and IFN-γ. | 02-27-2014 |
20140045888 | COMPOUNDS HAVING ANTIPARASITIC OR ANTI-INFECTIOUS ACTIVITY - Compounds of formula I: | 02-13-2014 |
20140044690 | High-Energy Compounds for Use in Alzheimer's and Other Neurodegenerative Diseases - A method of treating or preventing a neurodegenerative disease includes administering an effective amount of a compound to a subject in need thereof. The compound includes a high-energy compound, such as adenosine triphosphate (ATP), guanosine triphosphate (GTP), phosphocreatine (PCr), acetyl coenzyme A (ACoA), phosphoenol pyruvate (PEP), or a combination thereof. | 02-13-2014 |
20140042038 | MICROFLUIDIC ELECTROCHEMICAL GENOTYPING SYSTEM - The present invention provides an electrochemical devices and methods for detecting, measuring or monitoring gene expression by detecting hybridization of nucleic acids to arrays. A support wafer with at least one immobilized detection spot is joined with a well-generating wafer to form a sample well above each detection spot. Electrodes transmit electrical impulses upon sample detection from the sample well to an output connector, which are then read by an automated measurement device. The electrode is disposed on either the support wafer, well generating wafer, or on an electrode support wafer. An enzyme-associated probe detects hybridization of molecules to the array, through generation of electrical impulses. Optionally, electron transport mediators and dyes are used in conjunction with the enzyme to aid in detection. | 02-13-2014 |
20140040402 | SYSTEM AND METHOD FOR PREVENTING UNWANTED ELECTRONIC COMMUNICATIONS - An email system, configured by creating a user controlled email domain for each user, rather than a dedicated email address. The user is then allowed to create unlimited email addresses within the user controlled email domain. The system and method of the present invention provides improved policing of unwanted email communications. When unwanted communications on a compromised email address are detected, they can be identified and effortlessly subverted while known communicators may continue use of the compromised email address. | 02-06-2014 |
20140039381 | MULTICHANNEL TROCAR - A multi-channel trocar developed for use in minimal-access surgery/single incision laparoscopic surgery. The trocar permits surgical access of two or more articulating laparoscopic instruments or scopes through one skin incision using a dividing membrane to separate the working channels. This allows maximal use of robotic technology and permits more degrees of freedom at the operative site. The trocar is inserted through one single skin incision, in the usual manner. The trocar relocates the fulcrum and focal point of motion to the abdominal wall when using a set of interacting and interlocking diaphragms. | 02-06-2014 |
20140038913 | LUTEOLIN AND DIOSMIN/DIOSMETIN AS NOVEL STAT3 INHIBITORS FOR TREATING AUTISM - The present invention includes methods for the treatment of autoimmune disorders such as autism, schizophrenia, and type 1 diabetes. Flavonoids, luteolin, diosmin, and diosmin's aglycone form, diosmetin, were found to inhibit activation/phosphorylation of STAT3 induced by IL-6 in cultured neuronal cells. Furthermore, mice treated with diosmin showed a significant reduction of autistic phenotype induced by IL-6 through inhibition of STAT3 activation. | 02-06-2014 |
20140024883 | DEVICE AND METHOD FOR STIMULATING EYE MOVEMENT - A device for stimulating eye movement in a subject is presented. Stimulating eye movement through Accelerated Resolution Therapy (ART) allows the processing of information and elimination of negative body sensations. In an embodiment, a mechanical device is presented in which a physical object is attached to a motion mechanism which moves horizontally from left to right. In another embodiment, an electrical device is presented in which a computer-simulated object travels horizontally across a visual component. In a further embodiment, a computer software application is presented to track eye movements. The subject tracks the movement of the object with his eyes for a specific number of cycles in order to eliminate negative body sensations such as post-traumatic stress disorder. The device of the present invention may be used for sensation processing by the general public and may be used for ART by a trained therapist. | 01-23-2014 |
20140023588 | METHOD OF DRUG DELIVERY BY CARBON NANOTUBE CHITOSAN NANOCOMPLEXES - Functionalized Single Wall Carbon Nanotube (SWCNT) complexed with nanochitosan for use in the delivery of bioaffecting substances and diagnostic applications. fSWCNT complexed with the chitosan NG042 were used for delivery of DNA-encoding EGFP reporter protein and peptide. The results demonstrate that shown CNT-chitosan hybrid nanoparticles exhibit significantly higher transfection efficiency in vivo than chitosan alone. Furthermore, the functionalized nanotubes were tested for peptide transfer into HEK293 cells. The results showed that the hybrid nanoparticles efficiently transferred peptides. Together, these results show that hybrid SWCNT-chitosan particles increase DNA and peptide transfer into cells. | 01-23-2014 |
20140018692 | METHOD AND APPARATUS FOR PULMONARY VENTILATION IMAGING USING LOCAL VOLUME CHANGES - The invention provides a novel method of high-resolution quantifiable pulmonary regional ventilation imaging using a package of computer programs, including deformable image registration and local volume change calculation on 4-D or breath-hold CT images. High resolution 3D ventilation images have been generated using this technique with superior quality. The deformation matrices between different respiration phases are calculated using deformable image registration and applied to calculate local volume change ΔV between respiration phases. The invention provides less image-noise and mismatch sensitivity than other techniques based on CT images, and is less expensive than nuclear medicine imaging. Implemented clinically, the method can derive a patient's pulmonary ventilation information from the same set of 4-D CT images, providing a cheaper but more accurate method to generate clinical lung ventilation image. Such information can be utilized in treatment planning sparing functional lung volumes without additional procedure and cost for lung functional imaging. | 01-16-2014 |
20140008307 | TWO-STAGE MICROFLUIDIC DEVICE FOR ACOUSTIC PARTICLE MANIPULATION AND METHODS OF SEPARATION - Exemplary embodiments of the present disclosure provide for two-stage microfluidic devices using surface acoustic waves, methods of use thereof, methods of making, methods of focusing and separating particles, and the like. | 01-09-2014 |
20140007925 | INVERTED ORGANIC SOLAR MICROARRAY FOR APPLICATIONS IN MICROELECTROMECHANICAL SYSTEMS - The fabrication and characterization of large scale inverted organic solar array fabricated using all-spray process is disclosed. Solar illumination has been demonstrated to improve transparent solar photovoltaic devices. The technology using SAM has potential to revolute current silicon-based photovoltaic technology by providing a complete solution processable manufacturing process. The semi-transparent property of the solar module allows for applications on windows and windshields. The inventive arrays are more efficient than silicon solar cells in artificial light environments, permitting use of the arrays in powering microelectromechanical systems and in integration with microelectromechanical systems. | 01-09-2014 |
20130344169 | GENE SIGNATURE FOR THE PREDICTION OF RADIATION THERAPY RESPONSE - Described are mathematical models and method, e.g., computer-implemented methods, for predicting tumor sensitivity to radiation therapy, which can be used, e.g., for selecting a treatment for a subject who has a tumor. | 12-26-2013 |
20130338744 | GRAPHENE ELECTRODES ON A PLANAR CUBIC SILICON CARBIDE (3C-SIC) LONG TERM IMPLANTABLE NEURONAL PROSTHETIC DEVICE - Graphene, can be used to make an implantable neuronal prosthetic which can be indefinitely implanted in vivo. Graphene electrodes are placed on a 3C—SiC shank and electrical insulation is provided by conformal insulating SiC. These materials are not only chemically resilient, physically durable, and have excellent electrical properties, but have demonstrated a very high degree of biocompatibility. Graphene also has a large specific capacitance in electrolytic solutions as well as a large surface area which reduces the chances for irreversible Faradaic reactions. Graphene can easily be constructed on SiC by the evaporation of Si from the surface of that material allowing for mechanically robust epitaxial graphene layers that can be fashioned into electrodes using standard lithography and etching methods. | 12-19-2013 |
20130337149 | METHOD FOR MAKING SELF-ASSEMBLING, COLLAGEN-BASED MATERIAL FOR CORNEAL REPLACEMENT - A material derived from sea cucumber collagen fibrils is suitable for use in corneal replacements or as an implantable contact lens. To produce material, the collagen fibrils are centrifuged into orthogonal stacks of lamellae comprised of aligned fibrils. The resulting structure is a transparent film of arbitrary thickness very similar in structure to mammalian corneal tissue. | 12-19-2013 |
20130334455 | Magneto-Dielectric Polymer Nanocomposites and Method of Making - In accordance with the present invention, novel superparamagnetic magneto-dielectric polymer nanocomposites are synthesized using a novel process. The tunability of the dielectric/magnetic properties demonstrated by this novel polymer nanocomposite, when an external DC magnetic field is applied, exceeds what has been previously reported for magneto-dielectric polymer nanocomposite materials. | 12-19-2013 |
20130334112 | SYSTEM FOR SOLIDS RETENTION TIME UNCOUPLING BY SELECTIVE WASTING OF SLUDGE - Treatment systems are described which uncouple the solids retention time (SRT) of the recycling bacteria from the wasting bacteria. Elevated recycling bacteria SRTs increase concentrations of nitrifying bacteria in the aeration basin and Anammox bacteria in the anoxic basin, improving nitrification and anaerobic ammonium oxidation. Fluorescence in situ hybridizations were used to identify and determine the abundance of nitrifying bacteria and Anammox bacteria (recycling bacteria) in freshly settled sludge of biological nutrient removal (BNR) secondary clarifiers. An uneven distribution was observed for recycling bacteria in two BNR systems. Settling patterns suggest microcolony formation processes are sensitive to the internal recycle rate, which allow for rapid recycling bacteria microcolony growth by increasing circulation of flocs through the aeration and anoxic basins. Uncoupling the SRT enhances aeration and/or anoxic basin utilization and reduces the overall hydraulic residence time. | 12-19-2013 |
20130330384 | MOLECULARLY IMPRINTED POLYMERS HAVING AFFINITY FOR NATRIURETIC PEPTIDES - The present invention concerns molecularly imprinted polymers (MIPs) having an affinity for natriuretic peptides, such as atrial natriuretic peptide (ANP). In some embodiments, the MIP is a nanoparticle (a molecularly imprinted polymeric nanoparticle (MIPNP)). Other aspects of the invention include methods of preparing an MIP having affinity for a natriuretic peptide, methods for binding a natriuretic peptide in vitro or in vivo using an MIP of the invention, methods for interfering with the binding of a natriuretic peptide with its receptor in vivo, methods for reducing inflammation, cell growth, cell differentiation, or a cell proliferation disorder, methods for detecting natriuretic peptides, and devices and kits for sequestering and/or detecting natriuretic peptides. | 12-12-2013 |
20130327709 | METHOD AND SYSTEM FOR TREATING WASTEWATER AND SLUDGES BY OPTIMIZING sCO2 FOR ANAEROBIC AUTOTROPHIC MICROBES - The present invention describes a method of optimizing CO | 12-12-2013 |
20130296643 | FLARED VAGINAL STENT - The invention is a flared vaginal stent comprising a cylinder with a flared, grooved tip. The flared tip has a partially flat surface and a curved opposite surface. The stent is designed to mimic the shape of the human vagina and is used to display the front and back surfaces of the vagina so as to facilitate placement and attachment of a graft to the full length of the anterior and posterior walls of the vagina. The flare is designed to flatten out the proximal vagina, in keeping with the natural flared shape of the proximal vagina. The flat surface is designed to allow suture placement for the full length of the vagina for attachment of the graft anteriorly. The curved posterior surface is designed to highlight the posterior surface of the vagina to aid suture placement on the posterior (underside) of the vagina. | 11-07-2013 |
20130291135 | TRANSGENIC MODEL OF ALZHEIMER'S DISEASE - Evidence indicates dysregulation. of the immunoregulatory molecule CD45 occurs in Alzheimer's disease (AD). Transgenic mice overproducing amyloid-β peptide (Aβ) and deficient in CD45 (PSAPP/CD45 | 10-31-2013 |
20130289280 | NOVEL PHARMACEUTICAL FORMS, AND METHODS OF MAKING AND USING THE SAME - Crystalline salts, polymorphs, solvates, and hydrates of bicalutamide, 5-fluorouracil, donepezil, anastrozole, nelfinavir, mirtazapine, lansoprazole, and tamsulosin, or derivatives thereof are provided by the subject invention. Methods of making and using the same are also provided. | 10-31-2013 |
20130288342 | POST PROTEIN HYDROLYSIS REMOVAL OF A POTENT RIBONUCLEASE INHIBITOR AND THE ENZYMATIC CAPTURE OF DNA - The present invention concerns compositions and methods of extracting infectious pathogens from a volume of blood. In one embodiment, the method includes the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The present invention also concerns materials and methods for removing aurintricarboxylic acid (ATA) from a sample. | 10-31-2013 |
20130284242 | PARTIALLY-SPRAYED LAYER ORGANIC SOLAR PHOTOVOLTAIC CELL USING A SELF-ASSEMBLED MONOLAYER AND METHOD OF MANUFACTURE - The fabrication and characterization of large scale inverted organic solar array fabricated using all-spray process is disclosed. Solar illumination has been demonstrated to improve transparent solar photovoltaic devices. The technology using SAM has potential to revolute current silicon-based photovoltaic technology by providing a complete solution processable manufacturing process. The semi-transparent property of the solar module allows for applications on windows and windshields. The inventive modules are more efficient than silicon solar cells in artificial light environments. This significantly expands their use in indoor applications. Additionally, these modules can be integrated into soft fabric substances such as tents, military back-packs or combat uniforms, providing a highly portable renewable power supply for deployed military forces. | 10-31-2013 |
20130282050 | LAPAROSCOPIC TOOL FOR GRASPING TISSUE - A laparoscopic tool includes a base having a bore that receives the proximal end of an elongate outer tube having a lumen in axial alignment with the bore. An elongate inner rod is slideably mounted in the lumen and the bore. A clamp is detachably secured to a distal end of the elongate inner rod. A handle controlled by a user advances and retracts the inner rod. A nitinol clamp is connected to the distal end of the inner rod and an electrically conductive suture thread holds the clamp to the inner rod. A wedge block positioned at the proximal end of the inner rod has a slit that releasably engages the suture thread so that the suture thread is pulled until it is taut and wedged into the slit. The clamp closes when heated by an electrical current flowing through the suture thread and opens when the current stops. | 10-24-2013 |
20130280847 | TRANSPARENT CONTACTS ORGANIC SOLAR PANEL BY SPRAY - A method of fabricating organic solar panels with transparent contacts. The method uses a layer-by-layer spray technique to create the anode layer. The method includes placing the substrate on a flat magnet, aligning a magnetic shadow mask over the substrate, applying photoresist to the substrate using spray photolithography, etching the substrate, cleaning the substrate, spin coating a tuning layer on substrate, spin coating an active layer of P3HT/PCBM on the substrate, spray coating the substrate with a modified PEDOT solution, and annealing the substrate. | 10-24-2013 |
20130263916 | ALL SPRAY SEE-THROUGH ORGANIC SOLAR ARRAY WITH ENCAPSULATION - An inverted organic solar photovoltaic cell is described that may be fabricated onto rigid or flexible substrates using spray-on technology to apply the various layers of the cell. Indium tin oxide with a thin layer of cesium carbonate functions as the cathode for the novel inverted cells. An active layer of poly-3(hexylthiophene) and [6,6]-phenyl C61-butyric acid methylester having a thickness around 200 nm to 600 nm facilitates a high level of light transmittal through the cell. A modified PEDOT:PSS, made by doping a conductive polymer with dimethylsulfoxide (DMSO), functions as the anode. A method of forming the inverted organic solar photovoltaic cell is also described using gas-propelled spraying to achieve thin layers. After the layers are formed, the cell is sealed using a vacuum and temperature-based annealing and encapsulation with UV-cure epoxy. | 10-10-2013 |
20130255757 | ORGANIC PHOTOVOLTAIC ARRAY AND METHOD OF MANUFACTURE - The fabrication and characterization of large scale inverted organic solar array fabricated using all-spray process is disclosed, consisting of four layers; ITO-Cs | 10-03-2013 |
20130251752 | CHEMOKINE GENE-MODIFIED CELLS FOR CANCER IMMUNOTHERAPY - Described herein are methods of cancer immunotherapy, particularly compositions comprising genetically-modified cells that express macrophage colony stimulating factor (GM-CSF), CD40 ligand (CD40L), and chemokine C-C motif ligand 21 (CCL21), wherein the population of cells comprises bystander cells and target cancer cells, and methods of making these compositions and treating cancer using these compositions. | 09-26-2013 |
20130250240 | ADAPTIVE OPTICS OPHTHALMIC IMAGER WITHOUT WAVEFRONT SENSOR OR WAVEFRONT CORRECTOR - The invention utilizes a digital holographic adaptive optics (DHAO) system to replace hardware components in a conventional AO system with numerical processing for wavefront measurement and compensation of aberration by the principles of digital holography. Wavefront sensing and correction by DHAO have almost the full resolution of a CCD camera. The approach is inherently faster than conventional AO because it does not involve feedback and iteration, and the dynamic range of deformation measurement is essentially unlimited. The new aberration correction system can be incorporated into a conventional fundus camera with minor modification and achieve high resolution imaging of a retinal cone mosaic. It can generate profiles of the retinal vasculature and measure blood flow. It can also provide real-time profiles of ocular aberration during refractive (Lasik) surgery and generate three-dimensional maps of intraocular debris. | 09-26-2013 |
20130243832 | POLY(VINYL BENZOATE) NANOPARTICLES FOR MOLECULAR DELIVERY - The present invention comprises poly(vinyl benzoate) nanoparticle suspensions as molecular carriers. These nanoparticles can be formed by nanoprecipitation of poly(vinyl benzoate) in water using Pluronic F68 as surfactant, to create spherical nanostructures measuring about 200-250 nm in diameter which are stable in phosphate buffer and blood serum, and only slowly degrade in the presence of esterases. Kinetics experiments in phosphate buffer indicate that 78% of the coumarin-6 was encapsulated within the polymer matrix of the nanoparticle, and the residual 22% of coumarin-6 was surface-bound and quickly released. The nanoparticles are non-toxic in vitro towards human epithelial cells (IC | 09-19-2013 |
20130236920 | POST PROTEIN HYDROLYSIS REMOVAL OF A POTENT RIBONUCLEASE INHIBITOR AND THE ENZYMATIC CAPTURE OF DNA - The present invention concerns compositions and methods of extracting infectious pathogens from a volume of blood. In one embodiment, the method includes the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The present invention also concerns materials and methods for removing aurintricarboxylic acid (ATA) from a sample. | 09-12-2013 |
20130217015 | HMGA2 AS A BIOMARKER FOR DIAGNOSIS AND PROGNOSIS OF OVARIAN CANCER - The subject invention pertains to uses of HMGA2 as a diagnostic biomarker for ovarian cancer and for prediction of a subject's resistance to cancer therapy. The methods of the subject invention are particular useful for early detection of epithelial ovarian cancer. | 08-22-2013 |
20130216605 | MICRO-RNAS MODULATING IMMUNITY AND INFLAMMATION - MicroRNAs are shown to be up- and/or down-regulated in inflammation and immune cells using a mouse model of asthma and regulatory T cells as source of RNA, respectively. Modulating the expression of these microRNAs can be effective in redirecting inflammation and immunity and hence, can be beneficial as biomarkers or as therapeutic agents against diverse human immunologic and inflammatory diseases. | 08-22-2013 |
20130213040 | METHOD AND SYSTEM FOR GENERATING POWER FROM LOW- AND MID- TEMPERATURE HEAT SOURCES - A method and system for generating power from low- and mid-temperature heat sources using a zeotropic mixture as a working fluid. The zeotropic mixture working fluid is compressed to pressures above critical and heated to a supercritical state. The zeotropic mixture working fluid is then expanded to extract power. The zeotropic mixture working fluid is then condensed, subcooled, and collected for recirculation and recompression. | 08-22-2013 |
20130209549 | MATERIALS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES - The subject invention concerns materials and methods for treating neurodegenerative diseases and conditions associated with aggregation of the microtubule-associated protein tau. A method of the invention comprises administering an effective amount of a heat shock protein 27 (Hsp27), or a biologically-active fragment or variant thereof, or a polynucleotide encoding the same, to a person or animal in need of treatment. In one embodiment, a heat shock protein 27 (Hsp27), or a biologically-active fragment or variant thereof, is contacted with or provided to a target cell. The target cell can be a neuron. In a specific embodiment, an Hsp27 is delivered to the target cell via a polynucleotide encoding an Hsp27 protein, or a biologically-active fragment or variant thereof. In one embodiment, a method of the invention comprises injecting (e.g., via stereotaxic injection) a polynucleotide expression construct of the invention comprising a polynucleotide encoding an Hsp27 protein directly into neural tissue of a person or animal. The subject invention also concerns compositions comprising i) a heat shock protein 27, or a biologically-active fragment or variant thereof, and/or ii) a polynucleotide encoding an Hsp27, or a biologically-active fragment or variant thereof. The polynucleotide can be an expression construct that provides for expression of an Hsp27 in a target cell. | 08-15-2013 |
20130203709 | ACYLSULFONAMIDES AND PROCESSES FOR PRODUCING THE SAME - The present disclosure relates to acylsulfonamides and processes for their preparation. The processes involve a target-guided synthesis approach, whereby a thioacid and a sulfonyl azide are reacted in the presence of a biological target protein, a Bcl-2 family protein, to form the acylsulfonamide. | 08-08-2013 |
20130189257 | USE OF PKC-IOTA INHIBITORS FOR THE TREATMENT OF BREAST CANCER - The subject invention pertains to uses of PKC-iota inhibitors for treatment of breast cancer. In one embodiment, the subject invention provides novel uses of 1H-imidazole-4-carboxamide, 5-amino-1-[2,3 -dihydroxy-4-[(phosphonooxy) methyl]cyclopentyl]-,[1R-(1α, 2β, 3β, 4α)] (ICA-1) and related compounds for treatment of breast cancer. The compounds of the subject invention have potent anti-proliferative effects against human breast cancer cells. The compounds of the subject invention also inhibit the phosphorylation of IKK-α/IKK-β, induce chromatin condensation, and/or induce DNA fragmentation in cancer cells. | 07-25-2013 |
20130184456 | HETEROCYCLIC MACROCYCLE TEMPLATED METAL-ORGANIC MATERIALS - A process for the preparation of a heterocyclic macrocycle-templated supramolecular metal organic material, the process comprising preparing a reaction mixture containing a metal, a heterocyclic macrocycle, and organic ligands and forming, in the reaction mixture, a heterocyclic macrocycle-templated metal organic material comprising the metal, the heterocyclic macrocycle and the ligands by template-directed synthesis with the heterocyclic macrocycle serving as the template and being encapsulated within a cage of the template metal organic material. | 07-18-2013 |
20130184353 | MATERIALS AND METHODS FOR REDUCTION OF PROTEIN TAU AND TREATMENT OF NEURODEGENERATIVE DISEASES - The subject invention provides a myricanol compound that is in predominant form of (+)-αR,11S-myricanol as compared to (−)-αS,11R-myricanol. In one embodiment, the (+)-αR,11S-myricanol is isolated from | 07-18-2013 |
20130165339 | SAPP-ALPHA AS A BIOMARKER FOR PREDICTION OF INFLAMMATORY AND AUTOIMMUNE-RELATED DISORDERS - The subject invention pertains to the use of amyloid precursor protein-alpha (sAPP-α) as a biomarker for prediction of a subject's risk of developing inflammatory and/or autoimmune-related disorders. In addition, the present invention provides methods for optimizing vaccine schedules and compositions, thereby preventing or reducing the risks of vaccine-induced inflammatory and/or autoimmune-related disorders. | 06-27-2013 |
20130164747 | Predicting Treatment Response in Cancer Subjects - The invention relates to methods of determining an appropriate cancer therapy for a subject based on intratumoral expression levels of a gene, such as the RRM1 or ERCC1 gene. Compositions and kits useful for the methods are also provided. | 06-27-2013 |
20130150550 | Antibiotic-Bound Poly(Caprolactone) Polymer - This invention is the design and synthesis of a caprolactone monomer which bears a pendant protected carboxyl group. This monomer has been copolymerized with caprolactone in varying ratios. After polymerization, the protecting group can be removed and an antibiotic can be attached as a new pendant group. The bioactivity of the antibiotic-bound poly(caprolactone) polymer is described. | 06-13-2013 |
20130144315 | UNIVERSAL LAPAROSCOPIC SUTURING DEVICE - A laparoscopic suturing device includes a handle and a shaft mounted to the handle. A toggle knob is adapted to rotate the shaft about its longitudinal axis. A pair of opposed jaws, each having a hollow structure, open and close relative to one another. A needle carrier and a needle holder are respectively slideably disposed in a lumen of a first and a second jaw. A needle has first and second pointed ends and is adapted to be press fit into the lumen of the first jaw with the first pointed end exposed and alternatively into the lumen of the second jaw with the second pointed end exposed. A spring-loaded pusher advances and retracts the needle carrier when the toggle knob is in a first position and advances and retracts the needle holder when in a second position. The tool assists a surgeon in suturing tissue captured between the jaws. | 06-06-2013 |
20130144163 | DRUG DELIVERY DEVICE FOR OVARIAN CANCER - A drug delivery device has been designed to directly deliver an agent to the ovaries through direct contact with the fallopian tubes. The device consists of three main components: a tubular inserter, a cylindrical chamber and a plunger. The device is a single-use applicator designed in a shape similar to a tampon to facilitate its insertion through the vagina and into the uterus. Positioning of the device centrally in the uterus is accomplished through the use of ultrasound. The chamber is inserted into the tubular inserter. Adjusting the length of the chamber inserted into the tubular inserter controls the amount of tubing released from the apertures in the tubular inserter. Ultrasound is used to ensure the proper placement of each tube at the entrance of each fallopian tube. The plunger is inserted into the chamber and adjustment of the plunger controls the amount of the agent released into the tubes. | 06-06-2013 |
20130130302 | POST PROTEIN HYDROLYSIS REMOVAL OF A POTENT RIBONUCLEASE INHIBITOR AND THE ENZYMATIC CAPTURE OF DNA - The present invention concerns compositions and methods of extracting infectious pathogens from a volume of blood. In one embodiment, the method includes the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The present invention also concerns materials and methods for removing aurintricarboxylic acid (ATA) from a sample. | 05-23-2013 |
20130130271 | POST PROTEIN HYDROLYSIS REMOVAL OF A POTENT RIBONUCLEASE INHIBITOR AND THE ENZYMATIC CAPTURE OF DNA - The present invention concerns compositions and methods of extracting infectious pathogens from a volume of blood. In one embodiment, the method includes the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The present invention also concerns materials and methods for removing aurintricarboxylic acid (ATA) from a sample. | 05-23-2013 |
20130130234 | POST PROTEIN HYDROLYSIS REMOVAL OF A POTENT RIBONUCLEASE INHIBITOR AND THE ENZYMATIC CAPTURE OF DNA - The present invention concerns compositions and methods of extracting infectious pathogens from a volume of blood. In one embodiment, the method includes the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The present invention also concerns materials and methods for removing aurintricarboxylic acid (ATA) from a sample. | 05-23-2013 |
20130129702 | MATERIALS AND METHODS FOR PREVENTION AND TREATMENT OF RNA VIRAL DISEASES - The subject invention concerns a method of inhibiting an RNA virus infection within a patient by increasing the amount of 2-5 oligoadenylate synthetase (2-5 AS) activity within the patient. Preferably, the preventative and therapeutic methods of the present invention involve administering a nucleotide encoding 2-5 AS, or at least one catalytically active fragment thereof, such as the p40, p69, p100 subunits, to a patient in need thereof. The present inventors have determined that overexpression of 2-5AS causes a reduction in epithelial cell damage, reduction in infiltration of mononuclear cells in the peribronchiolar and perivascular regions, and reduction in thickening of the septa in the lungs. Levels of chemokines, such as MIP1-α, are also reduced upon overexpression of 2-5AS. The subject invention also pertains to pharmaceutical compositions containing a nucleotide sequence encoding 2-5 AS and a pharmaceutically acceptable carrier, as well as vectors for delivery of the 2-5 AS nucleotide sequence. | 05-23-2013 |
20130129673 | USE OF ENDOGENOUS ANTIOXIDANT PROTEINS IN THE TREATMENT OF STROKE - Oligodendrocytes (OLs), the predominant cell type found in cerebral white matter, are essential for structural integrity and proper neural signaling. Very little is known concerning stroke-induced OL dysfunction. Infusion of human umbilical cord blood (HUCB) cells protects striatal white matter tracts in vivo and directly protects mature primary OL cultures from oxygen glucose deprivation (OGD). Microarray studies of RNA prepared from OL cultures subjected to OGD and treated with HUCB cells showed an increase in the expression of 33 genes associated with OL proliferation, survival, and repair functions, such as myelination. Immunohistochemistry showed antioxidant protein expression was upregluated in the ipsilateral white matter tracts of rats infused with HUCB cells 48 hrs after middle cerebral artery occlusion (MCAO). These results show expression of genes induced by HUCB cell therapy that could confer oligoprotection from ischemia. | 05-23-2013 |
20130122509 | POST PROTEIN HYDROLYSIS REMOVAL OF A POTENT RIBONUCLEASE INHIBITOR AND THE ENZYMATIC CAPTURE OF DNA - The present invention concerns compositions and methods of extracting infectious pathogens from a volume of blood. In one embodiment, the method includes the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The present invention also concerns materials and methods for removing aurintricarboxylic acid (ATA) from a sample. | 05-16-2013 |
20130119301 | METHOD OF MODULATED EXOTHERMIC CHEMICAL SYSTEMS THROUGH PHASE CHANGE MATERIALS - The chemical reactions modulation of temperature and dissipate heat through using phase change materials (PCM). Hydration of a mixture composed of encapsulated and/or non-encapsulated oxides such as calcium oxide and/or magnesium oxide and dehydrated and/or hydrated zeolite coupled with control of pH of mixture through compounds such as Citric acid, or combination exothermic mixes, such as Cao and Mg—Fe, provide sustained heat release and heat retention tailored by addition of PCMs. The modulation may include timed/controlled release from encapsulated reactants and may include particles with tailored size distribution and different burn characteristics. The phase change materials used include organics (paraffins, non paraffins and fatty acids) and inorganics (salt hydrates). The selection of PCM is based on compatibility with the reacting mix, added reacting aqueous medium, and the desired temperature the system is to be held constant or temperature range it is desired to be modulated. | 05-16-2013 |
20130115687 | POST PROTEIN HYDROLYSIS REMOVAL OF A POTENT RIBONUCLEASE INHIBITOR AND THE ENZYMATIC CAPTURE OF DNA - The present invention concerns compositions and methods of extracting infectious pathogens from a volume of blood. In one embodiment, the method includes the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The present invention also concerns materials and methods for removing aurintricarboxylic acid (ATA) from a sample. | 05-09-2013 |
20130115457 | POLYPEPTIDE ELECTROSPUN NANOFIBRILS OF DEFINED COMPOSITION - Electrospun nanofibrils and methods of preparing the same are provided. The electrospun nanofibrils comprise at least one polypeptide. A polypeptide can be dissolved in a solution, and the solution can be electrospun into a nanofibril. The solution can be added to a syringe or syringe pump, and an electric field can be applied to electrospin the at least one polypeptide. | 05-09-2013 |
20130109885 | POST PROTEIN HYDROLYSIS REMOVAL OF A POTENT RIBONUCLEASE INHIBITOR AND THE ENZYMATIC CAPTURE OF DNA | 05-02-2013 |
20130096591 | INCISION-LESS LAPAROSCOPIC INSTRUMENT - A laparoscopic instrument is placed into the abdomen without the creation of a skin incision. The laparoscopic instrument includes a shaft that does not exceed 1.6 mm in diameter. The shaft has a beveled end and is inserted into an abdomen similar to the placement of a needle, without use of a scalpel. Operating instruments are introduced into the abdomen through the umbilical port using a docking device, and are then docked to the beveled end of the shaft after the shaft is introduced through the abdomen. Multiple types of operating instruments can be placed on the beveled end of the shaft during the surgical procedure. Each operating instrument is docked with a holster during introduction into and withdrawal from the umbilical port and is removed from the holster only when in use. When removed from the holster it is locked to the shaft and cannot be dropped. | 04-18-2013 |
20130096061 | METHOD OF TREATING SKELETAL DYSPLASIAS USING VESSEL DILATOR - C-natriuretic peptide (CNP) has been shown to regulate proliferation of mouse and rat osteoblasts. Genetic deletion of CNP results in dwarfism. CNP effects on bone growth involve inhibition of MEK 1 and ERK 1/2 kinases mediated via the intracellular messenger cyclic GMP. Vessel dilator is another natriuretic peptide synthesized by the atrial natriuretic peptide gene whose biologic half-life is 12 times longer than CNP. Vessel dilator's biologic effects on proliferating cells are mediated via inhibiting MEK 1/2 and ERK 1/2 kinases via cyclic GMP. Vessel dilator was not studied previously on osteoblasts. CNP and vessel dilator were tested in dose-response studies enhanced human osteoblasts' proliferation, showing that vessel dilator has identical mechanisms of action to CNP but much longer biologic half-life and effects at lower concentrations. Vessel dilator exhibited therapeutic effect for use in human achondroplasia, short stature and osteoporosis by stimulating osteoblast proliferation. | 04-18-2013 |
20130095487 | Interferon-Gamma Response as a Diagnostic Test for Persistent Chlamydial Infections - The present invention provides a non-invasive, sensitive, and convenient diagnostic test for persistent Chlamydial infection and diseases arising from persistent Chlamydial infection. The present invention also provides kits for diagnosis of persistent Chlamydial infection. | 04-18-2013 |
20130087507 | USE OF CACTUS MUCILAGE AS A DISPERSANT AND ABSORBANT FOR OIL IN OIL-WATER MIXTURES - Despite advances in off-shore oil exploration and drilling technology, accidental oil spills do occur. Depending on their magnitude and location, irreparable damage may be inflicted on marine and coastal ecosystems. Emulsification of a water/surfactant /oil system results in the production of oil droplets and this depends on the formulation and composition variables, mixing characteristics and system preparation. Thus, research is ongoing on improving methods of cleaning up oil spills. Cactus mucilage was used to disperse and absorb oil from a simulated oil slick in different salt concentrations. Results show correlations between emulsion properties and interfacial characteristics of mucilage as function of aqueous phase salinity. Mucilage powder added to the oil floating on the water dispersed the oil film and absorbed the oil while remaining afloat, facilitates removal of the oil-mucilage aggregate. This invention is a competitive treatment for oil spill remediation with the added advantage of being more environmentally friendly. | 04-11-2013 |
20130072395 | METHOD FOR EARLY DETECTION OF CANCERS - The invention includes methods for detecting the presence of a neoplastic condition by comparing a sample level of a BIF-1 to a reference, wherein a low level of BIF-1 in the sample correlates with the presence of a neoplastic condition. Another method involves determining the risk of relapse, tumor recurrence and/or metastasis by determining a sample level of a Bif-1 to a reference level of Bif-1, wherein low sample levels correlate with a likelihood of relapse, recurrence and/or metastasis. Yet another method includes detecting the presence of a pre-neoplastic condition, such as prostatic intraepithelial neoplasia. The method involves measuring a level of a Bif-1 in a sample and comparing the level of Bif-1 in the sample to a reference level of Bif-1. High levels of Bif-1 in the sample correlate with the presence of the pre-neoplastic condition. | 03-21-2013 |
20130071945 | MATERIALS AND METHODS FOR CAPILLARY MICROEXTRACTION IN COMBINATION WITH HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY - Germania-based sol-gel organic-inorganic hybrid coatings were prepared for on-line coupling of capillary microextraction with high-performance liquid chromatography. A germania-based sol-gel precursor, tetra-n-butoxygermane and a hydroxy-terminated triblock copolymer, poly(ethylene oxide)-block-poly(propylene oxide)-block-poly(ethylene oxide), were chemically anchored to the inner walls of a fused silica capillary (0.25 mm I.D.). Scanning electron microscopy images of the sol-gel germania triblock polymer coating were obtained to estimate the coating thickness. The analyte distribution constants between a sol-gel germania organic-inorganic hybrid coating and the samples (K | 03-21-2013 |
20130071348 | NANOPARTICLES WITH COVALENTLY BOUND SURFACTANT FOR DRUG DELIVERY - The present invention concerns nanoparticles, compositions comprising the nanoparticles, methods for their production, and methods of using the nanoparticles for the delivery of biologically active agents (e.g., antibiotics or other drugs) to human or non-human subjects. In one embodiment, the nanoparticle is a “surfactant-free” nanoparticle in which the surfactant moiety is covalently attached to the backbone of the polymer. | 03-21-2013 |
20130068692 | ELECTROSPUN CACTUS MUCILAGE NANOFIBERS - Novel electrospun nanofibers and nanofibrous membranes, methods of manufacturing the same, and methods of using the same are provided. The nanofibers include a cactus mucilage, such as mucilage from | 03-21-2013 |
20130065837 | INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER - Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide. | 03-14-2013 |
20130059787 | METHODS OF USING HUMAN PROTEIN KINASE C DELTA VIII AS A BIOMARKER - RA treatment can improve cognition; promote neurogenesis; and regulate alternative splicing of genes, particularly by mediating mechanisms of 5′ splice site selection and generation of PKCδ alternatively spliced variants. Expression of PKCδVIII is an indicator of the levels of on-going apoptosis in neurons. In the aging brain, switching the isoform expression to PKCδVIII by RA could shield the cells from neuronal death. The inventors discovered that human PKCδVIII expression is increased in neuronal cancer and decreased in Alzheimer's disease. The data shows that PKCδVIII promotes neuronal survival and increases neurogenesis via Bcl2 and Bcl-xL. In addition, the trans-factor SC35 was found to be crucial in mediating the effects of RA on alternative splicing of PKCδVIII mRNA in neurons. The data described herein indicate that PKCδVIII can be used as a biomarker for neurological diseases such as cancers and Alzheimer's disease and as a tool for monitoring and evaluating treatment. | 03-07-2013 |
20130058932 | USE OF PKC-IOTA INHIBITORS FOR THE TREATMENT OF GLIOMA - The present invention pertains to use of PKC-iota inhibitors for treatment of glioma. In a specific embodiment, the treatment method comprises administering ICA-1 or a salt thereof to a subject with glioma. In another embodiment, the treatment method comprises contacting glioma cells with an effective amount of ICA-1 or a salt thereof. | 03-07-2013 |
20130045189 | METHODS OF TREATING STROKE THROUGH ADMINISTRATION OF CTX0E03 CELLS - The subject invention pertains to methods to enhance the therapeutic effects of cellular or drug treatment in various diseases and disorders. More particularly, the present invention provides methods of treating disorders by administering CTX0E03 cells to the patient, intravenously or intraarterially. The treatment is useful for neurodegenerative diseases, such as stroke. The CTX0E03 cells may be cryopreserved and/or passaged before administration into the patient. Administration of the CTX0E03 cells into stroke rat models was at or within 48 hours after stroke. Testing of the rat models through elevated body swing test to measure of neurobehavioral status at the time of transplant and repeated triphenyltetrazolium chloride (TTC) staining as a measure of infarct volume showed short term survival that provided significant protection from the stroke. | 02-21-2013 |
20130034598 | INHIBITORS OF AKT/PKB WITH ANTI-TUMOR ACTIVITY - The subject invention concerns materials and methods for inhibiting the Akt/PKB pathway. In one embodiment, a compound of the invention inhibits kinase activity and/or phosphorylation levels of Akt proteins. The subject invention also concerns methods for inhibiting or killing a cancer cell or other cell in which expression of an Akt protein is elevated or constitutively active, comprising contacting the cell with an effective amount of a compound of formula I. The subject invention also concerns methods for treating cancer or a tumor in a person or animal comprising administering an effective amount of a compound of formula I to the person or animal. | 02-07-2013 |
20130031851 | Modular Dwellings - In one embodiment, a modular dwelling comprises a beam connector comprising a body and multiple arms that extend out from the body, structural beams comprising outer sides that define elongated channels that extend along a length of the beams, each beam being connected to an arm of the beam connector, a locking means that secure the structural beams to their associated beam connector arms, and a structural panel that comprises multiple edges, at least one edge of the panel being received by a channel of at least one structural beam. | 02-07-2013 |
20130030480 | SYSTEMS AND METHODS FOR ANKLE SYNDESMOSIS FIXATION - In one embodiment, a fixation system includes an anchor adapted to be implanted within a first bone, a washer adapted to be associated with a second bone that is to be secured to the first bone, and a suture that is fixedly attached at one end to the anchor and that extends between the anchor and the washer in multiple passes, the suture being adapted to extend through a passage formed in the first and second bones. | 01-31-2013 |
20130030170 | ENANTIOSELECTIVE CYCLOPROPENATION OF ALKYNES - The cobalt(II) complex of new D2-symmetric chiral porphyrin 3,5-DiMes-ChenPhyrin, [Co(P2)], has been shown to be a highly effective chiral metalloradical catalyst for enantioselective cyclopropenation of alkynes with acceptor/acceptor-substituted diazo reagents such as α-cyanodiazoacetamides and α-cyanodiazoacetates. The [Co(P2)]-mediated metalloradical cyclopropenation is suitable to a wide range of terminal aromatic and related conjugated alkynes with varied steric and electronic properties, providing the corresponding tri-substituted cyclopropenes in high yields with excellent enantiocontrol of the all-carbon quaternary stereogenic centers. In addition to mild reaction conditions, the Co(II)-based metalloradical catalysis for cyclopropenation features a high degree of functional group tolerance. | 01-31-2013 |
20130029870 | MATERIALS AND METHODS FOR DIAGNOSIS OF ASTHMA - The present invention pertains to materials and methods for diagnosing and/or determining the prognosis and likelihood of developing asthma. In one embodiment, methods of the invention comprise the use of single nucleotide polymorphic markers of asthma. Markers of the invention are present in the atria natriuretic peptide (NPPA) gene, and serve as a marker for genetic susceptibility of a person or animal in developing asthma. | 01-31-2013 |
20130023403 | METAL ORGANIC MATERIALS AS BIOMIMETIC ENZYMES - A supramolecular assembly comprising a metal-organic molecular framework and a heterocyclic macrocycle guest molecule. The metal-organic molecular framework comprises cubicuboctahedral cavities, octahemioctahedral cavities and trigonal cavities in a 1:1:2 ratio, respectively, and the heterocyclic macrocycle guest molecule is hosted by the octahemioctahedral cavity. In a preferred embodiment, the heterocyclic macrocycle guest molecule is a heme. | 01-24-2013 |
20130018267 | ELECTRONIC CATHETER STETHOSCOPE - An electronic catheter stethoscope measures and analyzes acoustic fields and dynamic pressure variations in the gaseous or liquid fluid inside a conventional medical catheter that is positioned in a patient's urologic, digestive, reproductive, cardiovascular, neurological or pulmonary system. Measurement transducers are installed in a housing connectable to multiple preselected medical catheters. The transducers detect bodily functions that are transmitted to the preselected catheter from within the body. The transducers, housing, electrical interface and signal processing electronics are positioned outside the body. | 01-17-2013 |
20120305477 | SOLIDS RETENTION TIME UNCOUPLING BY SELECTIVE WASTING OF SLUDGE - Fluorescence in situ hybridizations were used to identify and determine the abundance of nitrifying bacteria and Anammox bacteria (recycling bacteria) in freshly settled sludge of biological nutrient removal (BNR) secondary clarifiers. An uneven distribution was observed for recycling bacteria in two BNR systems. Settling patterns suggest microcolony formation processes are sensitive to the internal recycle rate, which allow for rapid recycling bacteria microcolony growth by increasing circulation of flocs through the aeration and anoxic basins. Sludge containing high levels of recycling bacteria are selectively collected and separated from the remaining sludge, uncoupling the solids retention time (SRT) of the recycling bacteria from the wasting bacteria. Elevated recycling bacteria SRTs increase concentrations of nitrifying bacteria in the aeration basin and Anammox bacteria in the anoxic basin, improving nitrification and anaerobic ammonium oxidation. Uncoupling the SRT enhances aeration and/or anoxic basin utilization and reduces the overall hydraulic residence time. | 12-06-2012 |
20120297965 | Hybrid Body Armor - In one embodiment, hybrid body armor includes a ballistic fabric and a plurality of small ballistic plates arranged in a tightly packed array over the ballistic fabric. | 11-29-2012 |
20120294932 | Prostate Carcinogenesis Predictor - A method of detecting prostate tumorigenesis in a subject, the method including the steps of (a) obtaining a sample from the prostate of the human subject, (b) detecting quantitatively or semi-quantitatively in the sample a level of expression for PKC-ι and (c) comparing the expression level in (b) to a level of expression in a normal control, wherein overexpression of PKC-ι, with respect to the control, indicates the presence of prostate cancer in the subject. The present invention is based upon the discovery that PKC-ι levels are elevated during prostate tumorigenesis. Furthermore, the proliferation rate of the tumor correlates with the level of PKC-ι. The invention also provides methods of treating prostate cancer by administering to the subject a compound that inhibits the expression of PKC-ι. The compound can be a small interfering RNA (siRNA) molecule. | 11-22-2012 |
20120289420 | MICRORNA BIOMARKERS FOR AIRWAY DISEASES - The present invention provides miRNA biomarkers useful for diagnosis, prognosis, and/or treatment of airway diseases such as asthma, asthma exacerbation and nasal polyps. | 11-15-2012 |
20120270923 | NATRIURETIC PEPTIDE RECEPTOR AS A BIOMARKER FOR DIAGNOSIS AND PROGNOSIS OF CANCER - The invention pertains to biomarkers for clinical detection of malignancies, especially for early detection of cancers. More specifically, this invention pertains to the role of Natriuretic Peptide Receptor A (NPRA) in cancer (e.g., tumor) progression. Thus, the invention includes materials and methods for the detection and prognosis of malignancies. The invention also pertains to methods for treating malignancies. | 10-25-2012 |
20120269906 | TREATMENT OF SUICIDAL IDEATION OR BEHAVIOR USING INHIBITORS OF NICOTINIC ACETYLCHOLINE RECEPTORS - The invention concerns methods of treating suicidal ideation or behavior in a subject in need thereof, comprising decreasing endogenous nicotinic acetylcholine receptor (nAChR) activity in the subject; therapeutic packages for treating suicidal ideation or behavior; and methods for determining the efficacy of a treatment for suicidal ideation or behavior. In some embodiments, the treatment methods comprise administering to the subject an effective amount of an inhibitor of a nAChR, such as a lithium compound, mecamylamine, clozapine, or asenapine. | 10-25-2012 |
20120247960 | BIDIRECTIONAL ELECTROWETTING ACTUATION WITH VOLTAGE POLARITY DEPENDENCE - A novel electrowetting system for the smooth continuous movement of a droplet across a single circuit using a continuous applied voltage regardless of polarity. The actuation of the droplet is achieved by introducing a diode into the idealized electrical circuit of the electrowetting system. The diode is in parallel with a capacitor (dielectric) and effectively shorts the droplet on the side of a lower potential electrode so that the entire voltage drop is across the dielectric over the opposite electrode. This creates an energy imbalance that moves the droplet towards the higher potential. If the voltage polarity is reversed, the direction of actuation will reverse as well. | 10-04-2012 |
20120236120 | AUTOMATIC STEREOLOGICAL ANALYSIS OF BIOLOGICAL TISSUE INCLUDING SECTION THICKNESS DETERMINATION - Systems and methods are provided for automatic determination of slice thickness of an image stack in a computerized stereology system, as well as automatic quantification of biological objects of interest within an identified slice of the image stack. Top and bottom boundaries of a slice can be identified by applying a thresholded focus function to determine just-out-of-focus focal planes. Objects within an identified slice can be quantified by performing a color processing segmentation followed by a gray-level processing segmentation. The two segmentation processes generate unique identifiers for features in an image that can then be used to produce a count of the features. | 09-20-2012 |
20120234508 | MULTISTABLE SHAPE-SHIFTING SURFACES - Multistable shape-shifting surfaces that retain their effectiveness as physical barriers while undergoing changes in shape and that can remain stable in the various shapes. The shape changes include any motion that makes the surface more effective at performing its function, such as expansion, shrinkage, twisting, encircling, wiggling, swallowing or constricting. The shape-shifting surfaces include tiled arrays of polygonal cells, each cell including specifically-designed compliant flexures attached to specifically-shaped overlapping thin plates or shells. The surfaces remain stable by leveraging them during deformation to an extent that they cannot spontaneously return to the unstressed shape. Applications for such surfaces include micro-scale cellular engineering and macro-scale biomedical applications, recreational uses, national security, and environmental protection. | 09-20-2012 |
20120232631 | CUBIC SILICON CARBIDE IMPLANTABLE NEURAL PROSTHETIC - An implantable neuronal prosthetic and method of manufacture thereof includes at least one elongated electrode shank adapted for arrangement in the brain having at least one electrode contact disposed on its surface and arranged to electrically couple with said brain. The at least one elongated electrode shank is formed form a single crystal cubic silicon carbide. An insulation layer of amorphous, polycrystalline, or single crystal silicon carbide is disposed over the elongated electrode shank; the insulation layer of amorphous, polycrystalline, or single crystal silicon carbide is removed from the at least one electrode contact. Signal control electronics are attached to the at least one elongated electrode shank and are in electrical communication with the at least one electrode contact. In an embodiment, a plurality of the at least one elongated electrode shanks are arranged into a matrix. | 09-13-2012 |
20120232135 | (-)-Epigallocatechin Gallate Derivatives for Inhibiting Proteasome - A method of reducing tumor cell growth, the method including administering an effective amount of a compound having the formula: | 09-13-2012 |
20120202765 | EFFECTIVE TREATMENT OF ESOPHOGEAL ADENOCARCINOMA USING TRICIRIBINE AND RELATED COMPOUNDS - The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat esophogeal adenocarcinoma by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug. | 08-09-2012 |